ANNUAL REPORT 2020 ANNUAL Table of contents REPORT 2020 2020 01 Introduction p5 02 COVID-19 – Impact on cancer clinical trials p10 03 EORTC: In a nutshell p17 04 Changing EORTC Governance p26 05 Spotlight on our members p30 06 EORTC tumour & cross-discipline groups in 2020 p36 07 Infrastructure projects p74 08 EORTC ecosystem p80 09 Patient involvement in clinical research p82 TABLE OF 10 Our policy actions in 2020 p87 11 Fellowships p92 CONTENTS 12 Events & campaigns p96 13 2020 Financial overview p104 14 The EORTC Cancer Research Fund (ECRF) p106 15 Publications 2020 p120 16 Clinical Trials 2020 p132

ANNUAL REPORT 2020

INTRODUCTION

5 Introduction

FOREWORD BY DR DENIS LACOMBE, EORTC DIRECTOR GENERAL

Covid-19 made 2020 an especially to these challenges. Through collaboration, we can challenging year for the EORTC, but ensure that clinically relevant questions can work it also showcased our organisation’s to optimise treatments and define therapeutic strategies free of commercial interest. remarkable resilience in the face of adversity. Whilst we celebrated the launch of the EU’s Beating Cancer Plan, we made sure to highlight In relatively short time, we managed to transform the absence of treatment optimisation that is our entire organisation to a remote and vital to innovation in oncology. We are continuing virtual workforce still able to carry out research our efforts with policymakers to rectify this in the operations. Although we had to suspend patient Plan. The role of EORTC is being acknowledged recruitment into trials early in the pandemic, as it now appears in the Porto Resolution by the our network innovated and found Covid-safe EU Portugal presidency, as a solution for clinical ways to restart that improve patient survival research infrastructure in Europe. and quality of life. In 2020, we published 72 papers in leading cancer journals showcasing In 2020, EORTC embarked on producing a new the tremendous scientific output of our governance structure to ensure it remains community. sustainable in the future. As you will read, the ongoing reforms are strengthening our Ultimately, we could not proceed as planned scientific and organisational strategies whilst in Barcelona with our annual conference. But deepening our network connections. The new we successfully pivoted to a series of digital governance structure will be fully implemented events that actually engaged three times in 2022. more people than average with a total of "We managed to 6 500 delegates from more than 100 countries. All the adaptations we made this year would not have been possible without the dedication transform our entire Beyond the pandemic, conducting independent, and commitment of the EORTC network, organisation to a remote multidisciplinary clinical research remains committees, board and staff. Their efforts have challenging in Europe. The reasons are ensured that we continue with our mission and virtual workforce numerous, linked to changing regulatory to improve the survival and quality of life of still able to carry out frameworks, costs of drugs and bureaucracy. patients. research operations." EORTC lobbied the EU institutions at all levels extensively in 2020 to alert policymakers Denis Lacombe 6 EORTC Director General 7 Annual report 2020 MESSAGE FROM PROF BERTRAND TOMBAL, EORTC PRESIDENT Dear colleagues and friends, We showed that the EORTC remains a truly "Our new governance multidisciplinary organisation, attracting over No doubt 2020 has been one of the most 2.800 different cancer specialists including structure will bring challenging times for the EORTC in our 60-year organ specialists interested in clinical research. the network closer history. Our private and professional lives have We worked with 750 institutions across been profoundly disrupted by the massive influx 48 countries in 2020, bringing therapeutic together." of Covid-19 patients. A universal and deleterious solutions to patients across the globe. We also consequence has been the postponing of standard attracted many young investigators, the next care for many severe acute and chronic diseases. generation of principal researchers who will The long-term impact of the pandemic on cancer shape EORTC’s future. patients remains to be seen. As president of this organisation, I am proud of After a few weeks in the pandemic, we the work that the board and management have were expecting the worst for clinical trials, accomplished this year to adapt EORTC to the understanding that for many reasons these could changing landscape in clinical research. Our new have been seen as an additional burden in a governance structure will bring the network closer dramatic sanitary situation. together, ensuring that we ask the right research questions and develop effective clinical trials We must say that today we are proud and admiring that change practice and bring better outcomes of the resourceful adaptation of the organisation to patients. in recruiting and managing patients on our trials. Many strategies have been put in place, including As we head out of the pandemic and further the implementation of telemedicine to connect into the 21st century, it is clear that EORTC has the physicians with their patients remotely. an integral place in clinical cancer research. EORTC HQ have been monitoring the impact of Our global presence attracts many leading the pandemic on patient recruitment throughout investigators, clinical groups and organisations. the year and we saw a dip in April but the level of The results of the network’s research challenges recruitment resumed by June. the status quo in healthcare with the best in evidence-based science and data. EORTC’s study pipeline is robust with six new studies opened in 2020, 45 ongoing studies, EORTC has shown its colours as a robust 59 in protocol development and eight in regulatory organisation in 2020, continuously adapting and activation. Currently the EORTC portfolio progressing to improve the lives of cancer patients. encompasses 208 studies at various levels of development. In 2020, we had 2.614 patients enrolled in clinical trials with a further 3 111 patients screened for potential trials. Bertrand Tombal EORTC President ANNUAL COVID-19 – Impact on cancer clinical trials REPORT 2020

Since patients with cancer are more susceptible to Covid-19 than the general population, EORTC clinical trials have been significantly impacted during the pandemic.

Beginning in 2019 we observed that many sites suspended recruitment as seen in the graph. While some sites decreased their monthly accrual, others stopped altogether. Once sites began gradually recruiting patients again in 2020, the recruitment rate stabilised. Note that the small drops between February and August 2020 are due to the end of recruitment of phase III trials and COVID-19 are unlikely due to the pandemic.

450 400 IMPACT ON 350 300 250 200 150 CANCER 100 50 0

CLINICAL Number of patients recruited in EORTC clinical trials Covid-19 first year (sep 2019 - aug 2020)

TRIALS Sites also took measures to limit patient visits to hospital and to concentrate resources on treating those patients affected by the pandemic. Measures included organising drug shipment to patients’ homes, when feasible, and cancelling monitoring visits to the hospital or proposing virtual visits.

Activities supported by logistics companies were largely unaffected. As a rule, drug shipment to the hospitals continued and only a minority of sites reported blocked or delayed biological sample collection and shipment.

10 11 Annual report 2020 COVID-19 – Impact on cancer clinical trials

Beyond clinical studies, we realised some significant silver-linings from the pandemic as an organisation. In general, a majority of Groups also saw higher turnout during virtual events than conventional in-person meetings. Young researchers especially enjoyed the increased access to experts with all the free, virtual meetings.

site staff, and provide continuous support, including tracking of investigational medicinal products in stock at the sites and timely resupply. On-site monitoring activities gradually re-started from June 2020 in Belgium, including remote monitoring for high-priority visits. Other countries gradually followed starting in July based on authorisation from sites and governments. Impact on EORTC headquarters To cope with the Covid-19 workload, new initial There were certainly concerns site submissions were put on hold and then Following guidance from the Belgian government, of clinical trials during and after the pandemic, deprioritised until the workload allowed for amongst patients, relatives and all EORTC HQ staff have been working remotely advising study teams accordingly. resumption. Work continued, however, on initial healthcare providers in since mid-March 2020. Our IT team put in place submissions and amendments that started prior “ infrastructure to provide adequate support for Safety reporting from sites was not affected and to the pandemic. the early phase of the pandemic, remote working. the number of serious adverse events was stable potentially resulting in less as well. HQ collected additional Covid-19 data Not all clinical trial activities were significantly The transformation to remote work led in the clinical study database of ongoing and impacted beyond the move to remote working. willingness to participate in to an increase in internal communication, new trials. Guidance related to vaccination was Since data return from sites was not affected, clinical trials and visit large documentation, and reporting to assess the prepared and sites were encouraged to report data cleaning activities continued. Similarly, academic centres involved in the impact of the pandemic on patient recruitment, Covid-19 vaccinations as concomitant medication statisticians maintained their regular activity with treatment and visit schedules as well as on data as well as any potentially related adverse events the addition of Covid-19 monitoring. Covid-19 response. collection, investigational medicinal product and from vaccination. human biological material management. We will assess the full impact of the pandemic on All on-site monitoring visits from mid-March EORTC HQ when more detailed information on HQ has continuously monitored daily reports from 2020 were cancelled and most could not be the final gap in recruitment and the final number Prof. Michael Weller the European Medicines Agency and 28 countries rescheduled. Clinical research assistants of protocol amendments is available. At the time of Chair of the EORTC Brain Tumour Group regarding the evolving guidelines for management were able to perform remote monitoring with writing this report, site reopening for recruitment 12 has started and accrual is back at expected levels. 13 Annual report 2020

The children of the EORTC staff participated in a drawing contest in April 2020 to show their support to the healthcare workers.

14 ANNUAL REPORT 2020

Covid-19 severely impacted elderly populations and led to a temporary stop in “clinical research. Once Covid adaptations were made, however, we succeeded in resuming activities including hosting a virtual autumn meeting with especially high attendance. EORTC:

Prof. Antonella Brunello IN A NUTSHELL Chair of the EORTC Cancer in Elderly Task Force

16 Annual report 2020 EORTC in a nutshell

Our synergistic network of institutions offers EORTC Uniquely positioned a transnational platform with unmatched quality to lead and efficiency, and research capabilities for rare IN A NUTSHELL cancers and long-term follow-up. We deliver robust data sets and are committed to generating EORTC serves as a crucial independent and solid medical evidence. Despite the advancements in clinical research over the past decades, cancer remains multi-tumour hub in the clinical research world the second leading cause of death globally. It is responsible for about 10 million deaths with unique global research infrastructure. This In today’s complex regulatory environment, our 1 per year and one in six deaths globally. is the added value we offer to international and experts ensure EORTC activities meet the strictest European communities of clinical researchers. quality and reliability requirements. In 2020, breast cancer became the most common in terms of new cases, compared to lung cancer in 2019.2 Yet, cancer continues to impact men overall at a higher rate. One Our work spans across tumour types, disciplines and With EORTC, patients are active participants in in eight men and one in 10 women are likely to develop cancer during their lifetimes.3 national borders. We specialise in pan-European clinical research. We seek their perspective in and international clinical and translational research questions and use their insights to better Most other tumour types bear similar challenges and some such as rare tumours are research that would be impossible on a national balance academic knowledge with understanding in great need for further therapeutic progress. Even if successfully treated, longterm scale. by the general public. survival and care remains a significant challenge. In addition, multidisciplinary treatment of cancer needs continued optimisation.

This is the stark reality that fuels our purpose and inspires our mission to prolong survival and improve quality of life of cancer patients. It is why we work so relentlessly International to ensure that cancer remains an urgent priority on the global public health agenda. As the largest cancer fighting clinical research organisation in Europe, we are uniquely positioned to lead and deliver practice-changing results.

1. World Health Organization – Cancer Key facts 2020 (Cancer (who.int)) Compliant with 2. World Health Organization – Cancer Key facts 2020 (Cancer (who.int)) Independent 3. World Cancer Report 2020 (www.iarc.who.int/) regulation

Prof. Gunnar Folprecht with a patient Universitaetsklinikum Carl Gustav Carus Multitumour Multidisciplinary Member of the EORTC Gastrointestinal Tract Cancer Group 19 EORTC in a nutshell

Five pillars of activity

Our clinical research is patient-centric and spans across tumours and disciplines. All EORTC activities fall into five fundamental pillars.

Knowledge Therapeutic Translational Research Delivering practice Academic Trials Translational research to collect biological changing results Academic clinical research to shed light material for analysis that can deepen our on the therapeutics agenda of cancer knowledge and understanding of cancer by optimising and ultimately changing biology and help guide patient treatments standards of practice. based on their own tumour Since 1962, EORTC has entered over 205 000 report analysis. patients in practice-changing clinical trials across tumour types, notably for brain, breast, prostate, melanoma, head and neck and soft tissue sarcoma. In 2020, 45 studies were open to 5 1 patient entry, bringing science and knowledge to patients for therapeutic improvement. Infrastructure Education Working with 139 collaborative groups worldwide, Infrastructure to promote Education to support EORTC demonstrates its capacity to bring more efficient and the next generation of investigators together to drive innovation in comprehensive cancer cancer researchers and cancer care. We play a key role in multidisciplinary, research that delivers high healthcare workers by international translational and clinical research, quality multidimensional 4 2 sharing knowledge and best taking basic science from the lab bench to datasets through practices, offering guidance the patient’s bedside. collaborations with partner and enabling dialogue on a organisations, institutions global scale. and hospitals. 3

HQ of the Future Accelerating Innovation Accelerating innovation to respond to rapid changes in healthcare with new pathways and mechanisms that increase survival and quality of life for patients.

21 Annual report 2020 EORTC in a nutshell

OUR MISSION Conferences & Trainings Publications IN NUMBERS 2020

6500+ 100+ Peer72 reviewed papers* Delegates Countries (incl. EORTC papers) EORTC's mission is to increase cancer patient survival and quality of life

Staff Network Patients involved in studies 238 32 3 Staff Members Nationalities Fellowships awarded in 2020 2805 750 Collaborators Institutions (members) >205,000 51% Patients in database 48 Countries 29% 71% 139 Male Female Collaborative groups 15% 18 27,000 EORTC groups Patients in & task forces Staff with Staff with MA follow-up PhDs in science

22 * Scientific medical journals 23 Annual report 2020 EORTC in a nutshell

50,25% Studies Conduct 47,27% Educational Grant 12,32% Academic

6 45 208 Ongoing Studies Studies per New studies activated Open to patient Study portfolio (+-)* by phase funding type 12,32% /category for 2020 entry studies LT Follow-up

8,87% 10,3% 18,23% 26 Activation Fully Supported EORTC Breast Pre-Development Cancer Group 10,34% 25 Development EORTC Radiation Legend Oncology Group • Pre-development: Board approves the study proposal and the Protocol Review Committee (PRC) approves the 20 protocol synopsis EORTC Lung Cancer Group • Development: full protocol is developed until PRC approval Legend 16 16 • Activation: period from protocol release until the first site EORTC Brain EORTC active, including regulatory submissions and approval • Academic: Study sponsored by EORTC or another 25 Tumour Gastrointestinal by authorities academic group which are self-funded, or funded by Group Tract Cancer academic grants Group • Conduct: patient recruitment and follow-up as pe protocol, concluding in a Final Analysis Report • Educational Grant: Investigator sponsored trials, funded 14 by industry EORTC 13 • Long-term follow-up: monitoring a person's health over Soft Tissue EORTC Head time after treatment, both during and after the study • Fully supported: Industry sponsored trials 20 and Bone and Neck Sarcoma Cancer Group Group 8 8 8 EORTC EORTC EORTC 7 Genito- Gynecological Melanoma EORTC Urinary Cancer Group Group Lymphoma 5 5 15 Cancers Group EORTC EORTC 4 Group Children's Quality EORTC 3 3 Leukemia of Life Group Leukemia Group EORTC EORTC Group Cancer in Cutaneous Elderly Lymphoma 1 1 1 Task Force Task Force EORTC EORTC EORTC Endocrine Imaging Infectious 10 Tumours Group Diseases Group Group

5

Studies per EORTC Tumour & Cross-discipline Groups ** * All studies with the following status: Pre-development, Open to Patient Entry, Closed to Patient Entry, Long-term follow-up ongoing, Development and Regulatory in process 24 ** All EORTC studies per group except the ones that are no longer active or the research projects that are not part of a group. Excluding also Quality Life Group external studies ANNUAL Changing EORTC Governance REPORT 2020 Modernising our governance

In order to keep EORTC sustainable for the future, EORTC reviewed its governance structure. This follows a number of discussions with internal and external stakeholders to understand how EORTC is functioning and the perception it has amongst the cancer community. We found that there was a lack of cohesion between the scientific and organisational strategies, there was disconnect between the EORTC network and board and with changing landscape in clinical research, the organisation was not adapting quickly enough. Following this diagnosis, EORTC set about changing the governance structure.

EORTC governance

GA

CHANGING BOARD COMMITTEES AC/FC NC OPERATIONAL ExCo COMMITTEES SAC EORTC BOARD CEO PRC/TRAC EORTC Fundraising IDMC

SCIENTIFIC GOVERNANCE CHAIRS COUNCIL EORTC HEADQUARTERS

G G G G G G G G G G G G G G G G TF TF

GA: General Assembly; AC/FC: Audit/Financial Cttee; NC: Nominating Cttee; ExCo: Executive Cttee; SAC: Scientific 26 Audit Cttee; CEO: Chief Executive Officer; PRC/TRAC: Protocol Review Cttee/ Translational Research Advisory Cttee; 27 IDMC: Independent Data Monitoring Cttee; G: Group; TF: Task Force Annual report 2020

Progress in Board 2020 Members TOMBAL Bertrand STUPP Roger President Past President

Our reforms in 2020 focused on placing The EORTC Director General has been re-named the scientific strategy and EORTC’s mission at to Chief Executive Officer (CEO). His role is the core of EORTC governance. Leaders of groups to oversee all EORTC’s operational and daily and task forces now form a newly created Scientific activities. The CEO acts as the guardian to ensure Chair Council (SCC). that the projects and scientific agenda deliver high-quality outcomes according to expected This council oversees the scientific strategy deliverables and timelines. The CEO reports LICITRA Lisa BAUMERT Brigitta EVRARD Serge van der GRAAF Winette Vice-President Secretary General Treasurer Chair of Translational Research and ensures the link between the science, to the Board, serving also as a non-voting Board Division the EORTC network and board. The Scientific member. Chair Council role will be to establish and propose the scientific strategy to the Board, The Protocol Review Committee (PRC) becomes monitor the strategy, feasibility and a standing committee which evaluates performance of EORTC’s portfolio and incoming studies in light of the principles maintain the EORTC portfolio in line with of the scientific strategy as developed by the strategy. Members strengthen cohesion the Scientific Chair Council and its prioritisation between Groups towards common EORTC goals. criteria. BIZZARI Jean-Pierre SCHILSKY Richard TEJPAR Sabine EISENHAUER Elizabeth They also ensure multi-disciplinary expertise Chair of New Drug Advisory Chair of Protocol Review Chair of Translational Research Chair of Scientific Audit and optimise EORTC capabilities across different Committee Committee Advisory Committee Committee groups and task forces. Members develop EORTC’s scientific strategy and propose it to the Board. The Chair of the SCC is a voting Board member.

The Board of Directors has also been reshaped to include specialties such as management and finance. This change has helped to ensure that operations better support scientific OLMOS David HEGI Monika VELIKOVA Galina LACOMBE Denis strategies across EORTC. The Board of Directors Our governance: roles Board Member Board Member Board Member EORTC Director General is the steering and executive body, advising the General Assembly on new activities and and responsibilities formulating proposals for ratification. The board drives EORTC’s mission, vision and values. It holds Please visit the EORTC website to have more the fiduciary responsibility of the organisation. It information about our governance's roles and appoints key EORTC officers at governance and responsibilities. Our committees can be found on group levels. the governance's page of the website. GOLFINOPOULOS Vassilis du MONCEAU Diego BENIADA Guy LUGOWSKA Iwona EORTC Director Headquarters (HQ) Chair, EORTC Cancer Research Chair, Independent Financial Permanent Guest, Early Career Fund Committee (IFC) Investigator (ECI) 28 29 ANNUAL Spotlight on our members REPORT 2020

Our clinical research covers all types of cancer tumours with an integrated approach to evaluate innovative agents and multimodal therapeutic strategies against current standard of care.

Our objective is to find the best solution for patients from both an efficacy and quality-of-life perspective. We conduct activities through tumour and modality-oriented research groups.

Beyond tumour-specific research, our experts examine every aspect of cancer therapy, including pharmacology and molecular mechanisms, pathobiology, radiotherapy and imaging.

In 2020, EORTC embarked on an ambitious membership renewal programme to ensure that all member information is accurate. The results showed that EORTC had over 2 800 direct members in 2020 from 750 institutions. Members came from 48 countries around the world, with the top 10 from Europe.

12% 11% 11% 9% 2% United Belgium Italy Spain Austria Kingdom 12% 11% 10% 5% 2% SPOTLIGHT Germany Netherlands France Switzerland Portugal ON OUR MEMBERS

Percentage of EORTC members per country in Europe

31 Annual report 2020 Spotlight on our members

Percentage of members per discipline (most frequent ones)

2% EORTC is a truly Psychologist multidisciplinary organisation spanning over 30 different 3% disciplines. In 2020, organ Radiologist specialists grew to comprise 15% of our membership. 3% Basic Researcher

3% Haematologist

3% Pathologist

7% Clinical Oncologist

8% Surgeon /Surgical Oncologist

14% Radiation Oncologist

15% Organ Specialist

34% Medical Oncologist

EORTC comprises 13 tumour and 5 cross-discipline groups:

Brain Breast Cutaneous Gastro lymphoma Endocrine Intestinal Genito-urinary

Gynecological Head & Neck Leukemia Lung Lymphoma Melanoma

Pharmacology Soft Tissue & Cancer in Imaging Pathobiology & molecular Quality of life Bones elderly mechanisms Annual report 2020 Spotlight on our members

EORTC network comprises institutions everywhere Institutions from in the world. outside Europe Australia 1 Brazil 2 Canada 5 Egypt 3 ISL Georgia 1 (1) SWE (11) FIN India 1 (4) Israel 9 NOR Japan 5 (12) Jordan 1 Qatar 1 EST RUS Reunion 1 (1) (1) Taiwan 1 USA 4 LVA (1) DNK LTU (9) (2)

IRL (7) GBR NED (86) (53) POL BEL DEU (13) (46) (110) CZE Group virtual LUX (7) UKR (2) SVK (2) meetings (2) AUS CHE (13) HUN FRA (26) SVN (5) Each EORTC Group meets twice a year to discuss (85) (5) ROM SRB (3) ongoing research and new project ideas. These (5) gatherings are a key opportunity to exchange HRV knowledge and insights whilst identifying (4) BGR (2) solutions to challenges, old and new. ITA MKD (92) (1) ESP TUR Over 2.000 members engaged in Group meetings PRT (56) (17) in 2020 that were largely virtual due to the (16) pandemic. The virtual accessibility made GRC attendance significantly higher than in 2019. (12) CYP Typically meetings are held in rotating locations, (3) but the popularity of virtual engagement may result in more hybrid meetings in the future.

34 35 ANNUAL REPORT 2020

EORTC EORTC is unique for conducting TUMOUR & trials across multiple tumours “with members stratified across Groups related to their tumour CROSS- of interest. It’s why we attract leading clinical researchers DISCIPLINE across the globe, and how we GROUPS IN conduct practice changing trials. 2020 Denis Lacombe EORTC Director General

36 Annual report 2020 EORTC tumour & cross-discipline groups in 2020

BRAIN TUMOUR GROUP

Mission Top results 2020

The Brain Tumour Group initiates and conducts research to challenge, re-define and develop standards Final results of the INTELLANCE 2 trial (EORTC 1410) indicated limited efficacy of the EGFR-targeted of care in emerging and controversial areas of diagnostic and therapeutic neuro-oncology. The Group antibody drug conjugate, Depatux-M, in combination with temozolomide in EGFR-amplified recurrent is especially focused on diffuse gliomas of adulthood of World Health Organisation grades two to four glioblastoma. as well as rare brain tumours. Members conduct joint projects with other EORTC Groups in the area of CNS metastasis. Analysis of our clinical trial database indicated that metformin is unlikely to prolong survival of patients with newly diagnosed glioblastoma.

Secondary analyses of EORTC 26101 defined MRI patterns associated with outcomes in bevacizumab-treated recurrent glioblastoma patients.

Members1 received the award for excellence in adult clinical research by the Society of Neuro-Oncology for the abstract entitled, "IDH1/2 wildtype anaplastic gliomas of the EORTC randomised phase III intergroup CATNON trial: overall survival related to treatment, MGMT status and molecular features of glioblastoma."

Michael Weller Jaap Reijneveld Frédéric Dhermain Chair Secretary Treasurer Universitätsspital Zürich, Amsterdam University Medical Institut Gustave Roussy, Switzerland Centre, The Netherlands France 12 514 Ongoing trials Members

38 39 1. C.M.S. Tesileanu, working with M. van den Bent and P. French and their team in Rotterdam. Annual report 2020

BREAST CANCER GROUP Mission Top results 2020

This Group aims to challenge, re-define and develop standards of care in all controversial areas of breast Launched working groups to develop clinical studies in elderly populations, locoregional treatment cancer diagnosis and therapy, including rare conditions such as male breast cancer. The Group’s research and new drug development. also contributes to long-term outcomes and follow-up of all patients until death. Focused on treatment of oligometastastic breast cancer with Imaging Group on a consensus document and support of the TAORMINA clinical trial that is under Board review.

Published results from the MINDACT study in peer-reviewed journals1 and presented at major conferences, including ASCO, EBCC and SABCS.2 The major finding related to the update of primary results with 8.7 years median follow-up. It confirmed the utility of low-risk 70-gene signature for withholding adjuvant chemotherapy in the presence of high clinical risk.

Appointed Prof Nadia Harbeck from the University of Munich as conference chair of the 12th European Breast Cancer Conference (EBCC). Attracting 2 439 delegates from over 80 countries in 2020, the conference is the only truly multidisciplinary conference in Europe for the breast cancer Etienne Brain Frederieke van Duijnhoven community. Chair Secretary Organised three lectures at the EBCC to offer young investigators practical advice to fund and publish Institut Curie - Hopital Rene Huguenin, France The Netherlands Cancer Institute-Antoni Van research and learn about statistical principles in clinical research. Leeuwenhoekziekenhuis, The Netherlands

15 486 Ongoing trials Members Michail Ignatiadis Kim Aalders Treasurer Young Investigator Institut Jules Bordet, Belgium Representative 1. Published two manuscripts, including one on the results of chemotherapy randomisation and another on step-wise Ziekenhuis Gelderse Vallei, The Netherlands procedure and comprehensive analysis of the MINDACT microarray dataset. 40 2. Conference presentations also included research projects on subgroups of patients with lobular breast cancer and 41 the use of systemic therapy in the MINDACT population. Annual report 2020

CANCER IN ELDERLY TASK FORCE

Mission Top results 2020

Geriatric oncologists have two main challenges: selecting patients for specific treatments and the delicate Continued with APPALACHES, a phase II study of Adjuvant Palbociclib as an alternative to balance of prolonging their survival, whilst maintaining independence and quality of life. Since elderly chemotherapy in elderly patients with high-risk ER+/HER2- early breast cancer in conjunction with patients are underrepresented in cancer clinical trials, producing evidence-based recommendations the Breast Cancer Group. in everyday clinical practice remains difficult. The Group conducts elderly-specific clinical research to meet these two challenges. Results from quality-of-life trial 75111 showed an increase in progression-free survival by seven months with the addition of metronomic oral cyclophosphamide to trastuzumab plus pertuzumab in older and frail patients with HER2-positive metastatic breast cancer.

Began discussions with the Soft Tissue and Bone Sarcoma Group and Quality of Life Group for a trial in older cancer patients with advanced sarcoma comparing standard doxorubicin versus metronomic cyclophosphamide. Now planning a 1976 intergroup trial, including several items for geriatric assessment.

Antonella Brunello Lissandra Dal Lago Andrea Luciani Chair Secretary & Young Treasurer Istituto Oncologico Veneto Investigator Ospedale San Paolo, Italy 3 225 IRCCS, Italy Representative Ongoing trials Members Institut Jules Bordet, Belgium

42 43 Annual report 2020 EORTC tumour & cross-discipline groups in 2020

CUTANEOUS LYMPHOMA TASK FORCE Mission

Cutaneous lymphomas are rare cancers that require a widely distributed, multidisciplinary network to effectively study. Operating as a task force, this Group is focused on testing new agents in collaboration Top results 2020 with industry and translational researchers. They regularly engage in prospective research for prognostic index development. Launched new trials including PROMPT study of extracorporeal photopheresis, MOGAT study with mogamuzilumab combination with TSE and REACH study with chlormethine gel.

Collaborated with more EORTC Groups and the International Rare Cancers Institute (IRCI) following the successful grant to develop a cutaneous T-cell lymphoma questionnaire for health-related quality of life. Recruitment has begun together with the Quality of Life Group including for a central review of PET scans with the Imaging Group.

Published a paper on the fundamental role of specialists in Dermatology–Venereology on the diagnosis and management of different types of skin cancer in collaboration with Julia Scarisbrick Antonio Cozzo the European Association of Dermato‐Oncology, European Academy of Dermatology and Chair Secretary Venereology, International Dermoscopy Society, European Dermatology Forum and the European Board of Dermato-Venereology. University Hospitals Birmingham NHS Kantonsspital St Gallen, Switzerland Foundation Trust (UHB) - Queen Elizabeth Medical Centre, United Kingdom

3 165 Ongoing trials Members Evangelina Papadavid Emmanuella Guenova Treasurer Young Investigator Athens University - Attikon University Representative General, Greece Lausanne University Hospital (CHUV), 44 Switzerland 45 Annual report 2020 EORTC tumour & cross-discipline groups in 2020

ENDOCRINE TUMOUR GROUP

Top results 2020 Mission Received EORTC approval for trial 1953, predicting tumour progression through molecular profiling in low-risk papillary thyroid cancer during active surveillance, in collaboration with the Head and Neck Cancer Group. The newly formed Endocrine Group is especially focused on identifying novel treatment options for aggressive forms of thyroid carcinoma (TC) and reducing the disease burden by minimising management Presented abstracts from EORTC trial 1559 at two international congresses. The first at ASCO in high-prevalent low-risk TC. on Nintedanib (BIBF1120)1 after first line therapy in progressive radioactive iodine refractory differentiated thyroid cancer. The full paper was submitted to EJC. The second at ESMO on Nintedanib (BIBF1120)2 after first line therapy in progressive medullary thyroid cancer.

Organised the first European thyroid cancer workshop in November 2020 to improve collaboration and co-ordination with other European groups involved in patient management of endocrine cancer.3

Launched a European survey on thyroid cancer genotyping to investigate if molecular analyses are the standard of care for patients in European countries. The results may impact access to tailored agents.

Collaborated with EURACAN on STARTER (Starting an Adult Rare Tumour European Registry) to build Johannes Smit Laura Locati Sophie Leboulleux a prospective European register of rare thyroid cancers such as radio iodine refractory differentiate thyroid cancers, medullary thyroid cancer and anaplastic thyroid cancer. Chair Secretary Treasurer Radboud University Medical Fondazione IRCCS Istituto Institut Gustave Roussy, France Center Nijmegen, The Nazionale dei Tumouri, Italy Netherlands 1 200 Ongoing trial Members

1. “Nintedanib (BIBF1120) after first line therapy in progressive radioactive iodine refractory differentiated thyroid cancer: a multicenter EORTC prospective randomized double-blind phase II study (EORTC protocol 1209-EnTF)” by Sophie Leboulleux et al. was accepted as poster presentation at ASCO and submitted for publication as a full paper in EJC. 2. “Nintedanib (BIBF1120) after first line therapy in progressive medullary thyroid cancer: a multicenter EORTC prospective 46 randomized double-blind phase II study (NCT01788982)” was accepted as an E-poster at ESMO. 47 3. Workshop partners included the European Thyroid Association (ETA), European Society of Endocrinology (ESE), European Reference Network (ENDO-ERN) and European Reference Network for Rare Adult Solid Cancers (EURACAN). Annual report 2020

GASTROINTESTINAL TRACT CANCER GROUP Top results 2020

Mission With 569 active members across 28 countries, the Group continues to hold a prominent place in the EORTC network. During the membership renewal process, many investigators confirmed their interest in the Group. This Group focuses on expanding knowledge of the genetic, epigenetic and immunologic backgrounds of Hosted a webinar to explore collaboration with biotechnology and diagnostics companies where gastrointestinal tumour diseases. Clinical trials focus on preclinical to clinical interaction and integrating Philips, Almac Diagnostics and Oncohost presented their portfolios followed by Q&As. early drug development, ensuring that new aspects of tumour biology are investigated with appropriate technology. Hosted a webinar to explore collaboration with pharmaceutical partners where E. Lilly, Novartis and Sanofi Genzyme presented their respective drug pipelines.

Dr. Elisa Fontana became Group Secretary and Prof. Manfred Lutz was appointed Treasurer.

Florian Lordick Elizabeth Smyth Chair Secretary University Cancer Center Leipzig, Germany Cambridge University Hospital NHS - Addenbrookes Hospital, United Kingdom

14 569 Ongoing trials Members Theo Ruers Elisa Fontana Treasurer Early Career Investigator leader The Netherlands Cancer Institute-Antoni Van Sarah Cannon Research Institute, Leeuwenhoekziekenhuis, United Kingdom 48 The Netherlands 49 Annual report 2020 EORTC tumour & cross-discipline groups in 2020

GENITO URINARY CANCERS GROUP

Top results 2020

Joined and actively enrolling for IMMUcan1, a more than € 30 million funded biomarker project involving various types of cancer using the SPECTA platform, involving 400 treatment-naïve metastatic renal cell carcinomas (RCC).

Co-operated with the Medical Research Council on SORCE2, a randomised controlled trial Mission investigating the role of Sorafenib as adjuvant therapy in RCC. Results published at JCO.

Actively recruiting and expanding collaboration to Brazil with LACOG for PEACE III3, a randomised This Group focuses on treating cancers of the urinary tract and male reproductive system. They are phase III trial comparing Enzalutamide vs. a combination of Ra223 and Enzalutamide in especially concentrated on clinical research for prostate cancer. Members are also interested in rarer asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to diseases and biomarker-driven research. bone.

Contributing to a project to assess differences in the exposure to Sunitinib in the immediate and deferred cytoreductive nephrectomy (CN) arms of the randomised controlled trial, SURTIME.4

Completed a research project with two manuscripts accepted for publication in JCO related to survival and new prognosticators in metastatic seminoma and predicting outcomes in men with metastatic non-seminomatous germ cell tumours.5

Axel Bex Jose Pablo Maroto Jan Oldenburg 7 441 Chair Secretary Treasurer Ongoing trials Members The Netherlands Cancer Hospital De La Santa Creu I Akershus University Hospital, Institute Antoni Van Sant Pau, Spain Norway 1. Integrated IMMUnoprofiling of large adaptive CANcer patient cohorts. 2. A phase III randomised double-blind study comparing Sorafenib with placebo in patients with resected primary renal cell Leeuwenhoekziekenhuis, carcinoma at high or intermediate risk of relapse (EORTC 30072). The Netherlands 3. A randomised multi-centre phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone (EORTC 1333). 50 4. Randomised phase III trial comparing immediate versus deferred nephrectomy in patients with synchronous metastatic renal 51 cell carcinoma (EORTC 30073) 5. Update of the International Germ Cell Cancer Classification Groups (IGCCCG) Analysis (RP 1538). Annual report 2020

GYNECOLOGICAL CANCER GROUP

Mission Top results 2020

EORTC has successfully conducted clinical research in ovarian, cervical, uterine and vulvar cancer for Finalised accrual of the 1508 trial, a phase II study of the anti-PD-L1 antibody atezolizumab, decades. Many of these trials were unique and changed clinical practice. Today, the Group is focused bevacizumab and acetylsalicylic acid to investigate safety and efficacy of this combination in on molecular approaches to attain truly multidisciplinary patient management. Their aim is to discover recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal adenocarcinoma. clinically useful predictive factors to identify subgroups of patients based on genomic patterns and activated pathways, and tailor clinical trials to them. The Group also stimulates clinical trials in rare Published review and meta-analysis of progression-free survival as a surrogate end point of overall cancers and underserved populations within gynaecology oncology. survival in first-line treatment of ovarian cancer.1

Published results of a randomised double-blind phase II study to evaluate the role of maintenance therapy with cabozantinib in high-grade uterine sarcoma after stabilisation or response to doxorubicin ± ifosfamide following surgery or in metastatic first line treatment.2

Collaborated with Quality of Life Group on a questionnaire related to ovarian cancer.3

Became a top recruiter for EORTC 1514, an EORTC QLG-GCG survivorship study that is a follow-up for gynecological cancer survivors.

Petronella Beatrix Fernanda Herrera Antonio Casado Ottevanger Secretary Herráez 4 288 Chair Centre Hospitalier Universitaire Treasurer Ongoing trials Members Radboud University Nijmegen Vaudois, Switzerland Hospital Universitario San Medical Centre, The Netherlands Carlos, Spain

1. JAMA Netw Open. 2020 Jan 3;3(1):e1918939. doi: (Published January 3, 2020) 52 2. International Journal of Gynecolical Cancer (EORTC62113).. 2020 Oct;30(10):1633-1637. doi: 10.1136/ijgc-2020-001519. Epub 53 2020 Jun 15. PMID: 32546554. 3. Gynecol Oncol. 2020 Nov;159(2):515-521. doi: 10.1016/j.ygyno.2020.09.007. Epub 2020 Sep 21. PMID: 32972782 Annual report 2020 EORTC tumour & cross-discipline groups in 2020

HEAD & NECK CANCER GROUP Mission Top results 2020

The Group’s research aims to contribute to better patient management at various stages of head and neck Submitted numerous proposals, six of which the Board has endorsed. One research project has since cancer by promoting and validating new treatments and examining individual responses to therapies. been approved and another is still in review. Oropharynx, oral cavity, larynx, hypopharynx cancers are focus areas along with locally advanced pharyngolaryngeal squamous cell carcinoma, pre-neoplastic lesions, salivary gland cancers, and Produced innovative ideas with novel concepts, including a study with alpha emitting particles and recurrent and/or metastatic cancer. SPECT-CT guided radiotherapy of the neck.

Launched a newsletter for young head and neck oncologists.

Christian Simon Sjoukje Oosting Chair Secretary Centre Hospitalier Universitaire Vaudois, University Medical Center Groningen, Switzerland The Netherlands

9 437 Ongoing trials Members Guy Andry Paolo Bossi Treasurer Young Investigator Institut Jules Bordet, Belgium Representative Universita Di Brescia - Azienda Ospedaliera 54 Spedali Civili di Brescia, Italy 55 Annual report 2020 EORTC tumour & cross-discipline groups in 2020

IMAGING GROUP Mission Top results 2020

This Group promotes the scientific and clinical value of imaging across modalities by spearheading Rapidly investigated the impact of Covid-19 on clinical trials, resulting in fast-track publication in the use of advanced techniques including translatable quantitative biomarkers, radiomic analyses, one of the leading European Imaging journals.1 and artificial intelligence to interrogate biologically-driven questions. Specialist interests also include successful delivery of immunotherapy and image-guided treatment (theranostics). Hosted themed plenary meetings featuring keynote lectures from world-renowned experts. The autumn theme revolved around concerns about MRI contrast agent safety and toxicity. The spring theme was on novel applications and theranostics opportunities for prostate cancer and imaging of the immune system.

Continued strengthening of transversal research through Group representatives and Disease Oriented Group liaisons. The success of the oligometastatic subcommittee on prostate cancer inspired strong collaboration with the Breast Cancer Group and the Gastrointestinal Tract Cancer Group.

Collaborated with the RECIST Group (Response Evaluation Criteria in Solid Tumours) to evaluate the Marion Smits Christophe Deroose uptake of iRECIST2 criteria since the publication of iRECIST guidelines. The RECIST Working Group and Chair Vice Chair the Hyper-Progression Task Force are also collecting images from patients under immunotherapy. Erasmus MC, The Netherlands U.Z. Leuven, Belgium Presented on how artificial intelligence applied to imaging can support clinical trials at a ‘Movember’ webinar by Prof. Luc Bidaut. The event was especially well attended.

1 2 232 Ongoing trial Research Projects Members Laure Fournier Lioe-fee de geus-oei Secretary Treasurer Hôpital Européen Georges Pompidou, Leiden University Medical Centre,

France The Netherlands 1. Deroose CM, et al., Impact of the COVID-19 crisis on imaging in oncological trials, Eur J Nucl Med Mol Imaging 2020;47:2054-8 56 2. The iRECIST approach allows responses not typically observed in traditional systemic treatment to be identified and better 57 documented. The guideline describes a standard approach to solid tumour measurement and definitions for objective change in tumour size which can be used in immunotherapy clinical trials Annual report 2020 EORTC tumour & cross-discipline groups in 2020

LEUKEMIA GROUP Top results 2020

Completion and follow-up of a large, hopefully practice-changing phase III trial on the comparison Mission of epigenetic therapy versus standard chemotherapy in first-line treatment of patients with acute myeloid leukemia.1

The Group focuses on improving outcomes for adult patients with acute leukaemia or related hematologic Active in the Survivorship Project to understand and improve long-term outcomes for acute myeloid malignancies, such as myelodysplastic syndromes. Members operate clinical trials, including large leukemia patients as part of the SPARTA trial.2 standard practice-changing phase III studies. One of their hallmarks are strong translational research programmes, that for example optimise epigenetic therapy in acute myeloid leukemia or myelodysplastic Engaged in HARMONY, the Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms syndrome. The Group is also engaged in survivorship studies in collaboration with the Quality of Life in HematologY.3 The project gathers, integrates and analyses anonymous patient data from diverse Group, taking advantage of the large number of patients already included in past phase III clinical trials. sources as part of the Big Data for Better Outcomes programme.

Michael Lübbert Heiko Becker Laimonas Chair Secretary Griskevicius 1 160 Universitätsklinikum Freiburg, Universitätsklinikum Freiburg, Treasurer Ongoing trial Members Germany Germany Vilnius University Hospital Santariskiu Santaros Clinics Klinikos, Lithuania

1. 10-day Decitabine Versus Conventional Chemotherapy ("3+7") Followed by Allografting in AML Patients ≥ 60 Years : a Randomized Phase III Study of the EORTC Leukemia Group, CELG, GIMEMA and German MDS Study Group. EORTC-1301-LG. 58 2. The Survivorship Project to understAnd and to impRove long-Term outcomes for Acute myeloid leukemia patients (SPARTA) - 59 RP-1479. 3. Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in HematologY (HARMONY) - RP-1655 Annual report 2020 EORTC tumour & cross-discipline groups in 2020

LUNG Top results 2020 Completed recruitment of two lung studies (1613 APPLE and 1525 Nivothym cohort 1) and launched CANCER GROUP a new study, Alkaline 1825.

Received a one-year funding extension for a statistician fellowship to analyse the MAGRIT database, Mission contributing to a future adjuvant trial and supporting more publications.

Despite Covid-19, actively recruited patients to studies and endorsed five new study proposals. This Group aims to challenge, re-define and develop standards of care for loco-regional as well as systemic treatments for lung cancer. This extends to mesothelioma and thymomas. Projects are designed Members now include over 50 early career investigators under 40 years of age who actively participate to integrate disciplines such as imaging, translational research, quality of life and quality assurance. as study co-ordinators in clinical studies, lead surveys to guide future study strategies and organise The Group is also focused on studying the use of immunotherapy to treat lung cancer. regular webinars.

Benjamin Besse Anne-Marie Dingemans Chair Secretary Institut Gustave Roussy, France Erasmus MC, The Netherlands As of December 2020: Anne-Marie Dingemans As of December 2020: Remon Masip Jordi Erasmus MC, The Netherlands HM Delfos Hospital-CIOCC, Spain

11 487 Ongoing trials Members Thierry Berghmans Matteo Giaj Levra Jessica Menis Treasurer Early Career Early Career Institut Jules Bordet, Investigator leader Investigator leader Belgium Centre Hospitalo-Universitaire Istituto Oncologico Veneto 60 de Grenoble, France Padova, Italy 61 Annual report 2020

LYMPHOMA GROUP

Mission Top results 2020

The Group is focused on Hodgkin Lymphoma (HL), a rare cancer. When treated correctly, HL can be Above expected inclusion in phase II EORTC 1537-COBRA trial1 on advanced stage Hodgkin lymphoma cured, but late toxicity (second cancers, cardiovascular diseases and fatigue) is a major concern. New despite Covid-19. trial initiatives aim to reduce both acute and late toxicity, whilst maintaining high cure rates. Research assesses all aspects of the disease to achieve a better basis for personalised treatment. Finalised the protocol for the new phase III RADAR trial2 in early favourable Hodgkin lymphoma (RADAR trial) in collaboration with University College London.

Developed a new study protocol for elderly Hodgkin lymphoma patients.

Released final results of a long-lasting trial on low-dose total body irradiation in low-grade stage I and II non-Hodgkin lymphoma.

Welcomed new investigators from Ireland and Poland who have become active Group members.

Igor Aurer Wouter Plattel Elly Lugtenburg Chair Secretary & Young Treasurer University Hospital Centre Investigator Erasmus MC, The Netherlands Zagreb, Croatia Representative University Medical Center Groningen, The Netherlands 9 215 Ongoing trials Members

1. 1537 COBRA trial investigates very early PET-response adapted treatment with BrAVD and BrECADD in patients with advanced 62 Hodgkin lymphoma 63 2. A randomised phase III trial with a PET response adapted design comparing ABVD +/- ISRT with A2VD +/- ISRT in patients with previously untreated stage IA/IIA Hodgkin lymphoma Annual report 2020

MELANOMA GROUP

Mission Top results 2020

The Group aims to improve the clinical care of patients suffering with cutaneous, mucosal or ocular Presented and published updated follow-up data confirming the relapse-free survival benefit of melanoma, and to increase knowledge about melanoma acquisition and progression. Group adjuvant pembrolizumab for high-risk stage III melanoma after complete surgical resection. sub-committees focus on topics including epidemiology, early-stage melanoma, surgery, pathology and systemic therapy (adjuvant and for advanced disease). Presented the first distant-metastasis-free survival data for adjuvant pembrolizumab for high-risk stage III melanoma after complete surgical resection, demonstrating a similar consistent effect on reducing distant-metastases, not just loco-regional recurrences.

Despite being unable to complete the predefined accrual, results still showed that adjuvant pegylated inferferon is an effective adjuvant treatment in stage IIB/C ulcerated primary melanomas compared to observation. This is especially valuable for developing countries without access to or reimbursement for newer melanoma treatments.

Developed a nomogram together with European Association of Dermato-Oncology (EADO) to help Alexander van Akkooi Paul Lorigan predict outcome of sentinel node positive melanoma patients to allow optimal selection for adjuvant therapy. Chair Secretary The Netherlands Cancer Institute - Antoni Van The University of Manchester and The Christie Added SOX10 to the EORTC pathology protocol as an immunohistochemical staining to assess Leeuwenhoekziekenhuis, The Netherlands NHS Foundation Trust, United Kingdom sentinel node metastases in melanoma.

6 369 Ghanem Ghanem Bastian Schilling Sara Valpione Ongoing trials Members Treasurer Young Investigator Young Investigator Institut Jules Bordet, Representative Representative Belgium University Clinic Wurzburg, The University of Manchester Germany and The Christie NHS 64 Foundation Trust, 65 United Kingdom Annual report 2020 EORTC tumour & cross-discipline groups in 2020

PATHOBIOLOGY GROUP Mission Top results 2020

Pathobiology research at EORTC aims to identify and validate biomarkers across cancer types that can be First results were received on the role of APOBEC3B in breast cancer therapy resistance, funded by used to develop new or more targeted treatments. The Pathobiology Group aims to actively contribute the Dutch Cancer Society. to clinical research within EORTC and to perform collaborative studies into biomarkers. Launched EUROSTAR1 to study reversal of endocrine resistance in metastatic breast cancer.

Released outcome of liquid biopsy studies in distinct tumour types: breast cancer (ctDNA in DCIS, circulating microRNA in HER2+ breast cancers, CTC and ctDNA in cholangiocarcinomas).

Received first omics-based results highlighting the molecular features of breast carcinoma cells with enhanced metastatic potential.

Co-operated with industry on novel therapeutic approaches in projects for head and neck, colorectal and ovarian cancers. Initiated a partnership with GeneTools LLC, headquartered in the US state of Paul Span Ira Skvortsova Oregon, to test antisense morpholinos that target oncofetal genes.

Chair Secretary Prof. Tamara Lah Turnšek received a life-time achievement in science award (“Zois award”) in Radboud University Medical Center Nijmegen, Innsbruck Universitätsklinik, Austria Slovenia. Mariela Vasileva-Slaveva received a Think Pink Europe Innovation Award for a project on The Netherlands As of September 2020: Leticia Oliveira-Ferrer the digital diaries of breast cancer patients. As of September 2020: Ira Skvortsova UKE - University Cancer Center, Germany Innsbruck Universitätsklinik, Austria Ira Skvortsova became Editor-in-Chief of the new journal, “Advances in Cancer Biology – Metastasis” (Elsevier), which will consider manuscripts on basic and translational cancer research.

134 25 174 Sites Countries Members

Maurizio Callari Gert Van den Eynden Treasurer Young Investigator Cruk Cambridge Institute, Representative United Kingdom 66 GasthuisZusters Antwerpen - SintAugustinus , 1. The project studies a new drug (SC101) from the company Scandion which can revert endocrine resistance. In this project we try 67 to understand the mechanism of action, we try to find biomarkers for patient selection to the compound and the project involves Belgium a clinical feasibility study in metastatic cancer patients. Annual report 2020 EORTC tumour & cross-discipline groups in 2020

PHARMACOLOGY & Top results 2020

MOLECULAR MECHANISMS Hosted annual meeting with 38 speakers and 124 participants in 9 sessions on immunotherapy, individualised therapy, DNA repair, novel therapeutics, tumour models and medicinal chemistry. (PAMM) Meeting included a special focus on bench-to-bedside studies. Began collaborating on projects with Disease Oriented Groups for lung, head and neck, and endocrine cancers as well as the Pathobiology Group.

Mission

This Group aims to stimulate preclinical and clinical research of anticancer drug effects and drug-related molecular pathology. PAMM is an integral part of the EORTC’s Translational Research Division, delivering information for projects with other disease-oriented groups, particularly in early-stage development.

Eric Raymond Elisa Giovannetti Annette Larsen Chair Secretary Treasurer 44 127 Groupe Hospitalier Paris Saint- Vrije Universiteit University Université Pierre et Marie Curie, Publications Members Joseph, France Medical Center, The Netherlands Hôpital Saint-Antoine, France collaborative papers

68 69 Annual report 2020 EORTC tumour & cross-discipline groups in 2020

QUALITY OF LIFE Top results 2020

GROUP Led the co-ordination and development of an Innovative Medicines Initiative (IMI)-funded project to develop international consensus recommendations for the design, analysis and interpretation of PRO data in cancer clinical trials.1

Developed 66 language versions of a telephone script for QLQ-C30 that became a valuable solution for many users during the pandemic, enabling them to collect QOL data when patients were confined Mission at home. Developed preliminary scripts as well for 19 modules that involve over 250 translations. Recruited patients for two prospective clinical trials to assess physical and or psychosocial problems after primary treatment using cross-sectional survey in gynaecologic cancer (EORTC-1514-GCG)2 This Group aims to better understand the effects of cancer and its treatments on health-related quality and breast cancer (EORTC-1617-BTG)3. of life for patients across diverse population groups and cultures. Members develop and refine related questionnaires for oncology clinical trials, other well-designed research studies and clinical practice. Received further funding for the TOLERANCE trial from Fonds Cancer (FOCA) and currently under They also collaborate with other EORTC research groups to implement studies in clinical trials. consideration by the Rising Tide Foundation to complete its funding. It is a purely academic clinical trial to reduce treatment burden in elderly sarcoma patients using the QLQ-C30.

Anne-Sophie Karin Kuljanic Susanne Singer Darlington Secretary Treasurer Chair Klinicki Bolnicki Centar Rijeka, Johannes Gutenberg School of Health Sciences, Croatia Universitätsklinikum - Mainz University of Southampton, University Medical Center, 36 412 Ongoing trials Members United Kingdom Germany As of Autumn 2020 Mieke Van Hemelrijck School of Cancer and Pharmaceutical Sciences, King’s College London, United 1. The project consortium involves the Setting International Standards in Analysing Patient-Reported Outcomes and Quality of 70 Kingdom Life Endpoints Data (SISAQOL) initiative 71 2. Follow-up in Gynecological Cancer Survivors: An EORTC QLG-GCG Survivorship Study 3. Follow-up in Early and Locally Advanced Breast Cancer Patients: An EORTC QLG-BCG- ROG Protocol Annual report 2020

SOFT TISSUE AND BONE SARCOMA GROUP

Mission Top results 2020

This Group conducts international clinical trials and other research projects to innovate multidisciplinary Published in Lancet Oncology and presented at ASCO on the STRASS trial, the first ever completed treatment strategies for patients with sarcoma that can improve survival and quality of life. Members randomised controlled trial in retroperitoneal sarcoma. This study evaluated the role of neo-adjvuant collaborate closely and across borders to conduct the breakthrough research that is needed for this radiotherapy for retroperitoneal sarcoma.1 heterogeneous group of rare and ultra-rare cancers. Launched the successor, STRASS 2 to evaluate on a global scale the role of neo-adjvuant chemotherapy for retroperitoneal sarcoma.

Published the CaboGIST trial, an important study evaluating cabozantinib as a treatment option for patients with gastrointestinal stromal tumours.

Developed several trial designs for immunotherapy strategies for sarcoma by young oncologists, hopefully leading to fully-funded and EORTC-led immunotherapy trials.

Approval of and funding for the first soft tissue and bone trial with QOL as the primary endpoint called TOLERANCE, a trial evaluating different chemotherapy regimens for elderly patients. Hans Gelderblom Winan van Houdt Ian Judson Chair Secretary Treasurer Leiden University Medical The Netherlands Cancer The Institute of Cancer Research Centre Institute-Antoni Van United Kingdom The Netherlands Leeuwenhoekziekenhuis As of November 2020: The Netherlands Jean-Yves Blay Centre Léon Bérard 12 365 Ongoing trials Members France

72 73 1. Bonvalot et al, Lancet Onc 2020 Oct;21(10):1366-1377. ANNUAL REPORT 2020 SPECTA

Precision oncology is the future of cancer treatment informed clinical decisions based on the genomic and through the SPECTA platform, EORTC is ‘best fit’ profile of patients. helping to lead the way. The pan-European platform allows for the rapid implementation of SPECTA aligns research into a single protocol new clinical trials and robust translational cancer and patient informed consent with one clinical research. database. With a centralised process, it ensures high-quality collection, storage of human The molecular tumour boards emerging from biological material as well as translational SPECTA enable clinicians to make far more research.

In 2020, three downstream SPECTA projects were actively enrolling patients and a new project was initiated. With the 4 current downstream projects, global SPECTA enrollment is expected to reach approximately 6 800 patients.

AYA IMMUcan Molecular landscape of brain and sarcoma Gaining knowledge of the interaction between cancer in adolescents and young adults. the tumor and its microenvironment and the This is a collaborative project with the German impact of therapeutic interventions Research Center DKFZ. The sarcoma cohort has fully recruited and closed. EORTC is the academic lead for this IMI funded INFRASTRUCTURE project.

Arcagen BioRadon Understanding the genomic of rare cancers. [Project under development] PROJECTS This is a collaborative project with the European Reference on Rare Adult Solid Cancer Molecular characterisation of NSCLC (non- (EURACAN). The Gastrointestinal and small cell lung cancer) and exposure to indoor endocrine cohorts have been fully recruited radon in Europe. andclosed. Radon is the leading cause of lung cancer in non- First publication in 20201 and poster at the ENA smokers, but the carcinogenesis mechanism in 2020 scientific meeting order to prevent future cases, remains unknown.

74 1 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709508/pdf/esmoopen-2020-001075.pdf Annual report 2020 Infrastructure Projectsprojects

SPECTA is a unique way to share at international level the results “of cancer molecular screening. It’s a model for drug development of rare actionable alteration and for identifying eligible patients The EORTC SPECTA platform in different countries. It’s a new is supported by WBA. paradigm for clinical research.

Prof Nicolas Penel SPECTA’s Principal Investigator 76 77 Annual report 2020 Infrastructure Projects

E²-RADIatE 2020 Highlights

It was a year to remember in more ways than one. We finished activating the 22 sites in our five ‘starting’ countries from our first wave of regulatory submissions. The second phase of 43 sites (including six new countries) is ongoing. We were happy to welcome the first site in Slovenia, and soon in Austria, Czech The E²-RADIatE platform gathers ‘real-world’ data on patients treated with radiation Republic, Germany, Poland, Portugal, Spain and the United Kingdom. oncology in Europe. The platform represents a unique collaboration between the EORTC and the European Society for Radiotherapy and Oncology (ESTRO) to build collective knowledge Despite Covid-19 restrictions, 441 patients were enrolled in the OligoCare cohort by the end of 2020. There on how treatments impact patient survival and quality of life. was a slowdown in March (only 16 patients enrolled), but numbers quickly recovered with an average of 36 patients/month until December. Enrolment has consistently exceeded expectations.

In 2021, we are finishing the second phase and further extending the number of sites as part of a third wave. We are also exploring a collaboration with Australian and Canadian centre as well as opening a new cohort on re-irradiation.

The excellent recruitment into The E²-RADIatE platform is a the OligCare cohort indicates unique joint initiative of the the strong commitment of the EORTC and the ESTRO, combining “Radiation Oncology community “the efforts of a major cancer to contribute to a better research organization with those understanding of oligometastatic of a large group of dedicated disease in general and of radiation oncology professionals. factors influencing outcome of The structured collection of oligometastatic cancer patients radiotherapy-specific real-world treated with radical radiotherapy. data will complement the evidence generated in clinical trials and shed additional light on the outcome of the treatments we deliver.

Matthias Guckenberger Yolande Lievens Cohort Coordinator of OligoCare E²-RADIatE Study Coordinator

78 ANNUAL EORTC Ecosystem REPORT We partner with organisations that share our mission to improve survival and quality of life for patients with cancer. Partners lend their expertise with clearly defined responsibilities in our structure, whilst 2020 adhering to EORTC’s principles of independence and quality.

EORTC has established an agreement 2020 New or renewed with Cancer Drug Development Forum (CDDF) to partner on the partnerships strategy for conferences and meetings.

EORTC ECOSYSTEM

EORTC continues its longstanding partnership with Walgreens Boots Alliance to support our translational research EORTC advocates for our mission infrastructure, SPECTA and public affairs agenda with EU policymakers at theEuropean 2020 marked the beginning of Medicines Agency (EMA) as an EORTC's collaboration with the 80 official network organisation. Anticancer Fund to 81support academic clinical trials. * EORTC is a member of those federations. ANNUAL Patient involvement in the research REPORT 2020 Patient Days 2020

EORTC held a two-day training course in The programme was developed in close February for European patients and patient collaboration with the EORTC patient representatives. It's aim is and help participants panel and is based on topics suggested understand cancer biology, and learn about by participants from previous editions. cancer biology, personalised cancer treatment Post-surveys showed that respondents regarded and care, regulatory aspects of clinical research, Patient Days positively, both in terms of drug development, real world data, and patient its programme and organisation. Afterwards, involvement in the design and implementation 12 participants applied to join EORTC’s Group of of clinical trials. Interactive sessions enabled Patient Experts. participants to debate on the topics with researchers and experienced patient advocates.

PATIENT “Before Patient Days, I didn't know where studies come from, how they’re carried out or how protocols are created. Now that INVOLVEMENT IN “I understand and know the people behind the research, I trust that they’re doing their best to improve quality of life. I feel like we’re THE RESEARCH headed in the right direction.”

82 83 Patient involvement in the research

EORTC PATIENT PANEL

Speakers at Patient New members Days

Roger Wilson and Janette Rawlinson are patient Five new members joined the patient panel in advocates who bring their lived experience 2020, bringing the total number to nine. Tom Patient involvement to the patient panel. At Patient Days, they Haswell, who was a member of the British spoke about patient needs in research and the Thoracic Oncology Group Steering Committee in the IDMC relevance of endpoints. They shared their cases and an influential professional lung cancer and moderated several sessions. advocate, sadly passed away in November.

Since our goal is to enhance patient involvement in different facets of cancer clinical research, we Patient involvement are currently considering appointing a patient in Groups representative as a member of the Independent Roger Wilson Kathy Oliver Janette Rawlinson Data Monitoring Committee (IDMC). A survey to Panel chairman, International NCRI lung subgroup, select the most suitable candidates for this role The changes to EORTC governance underway Sarcoma Patients EuroNet Brain Tumour Alliance (IBTA) British Thoracic Oncology has been developed in collaboration with the IDMC imply involvement of patient representatives in (SPAEN) UK Group (BTOG), European chair and its members. the Group steering committees. UK Lung Foundation (ELF) UK

Some numbers Patricia Fairbrother Rafal Nagiecki Eva Maria Independent Cancer Independent patient Strömsholm Patients' Voice (ICPV) advocate Gynaecological Cancer UK Poland Patients Finland 105 9 1 2 Patient reviewers Panel members face-to-face virtual Margaret Grayson Lesley Goodburn Winette van der Graaf meeting meetings Northern Ireland Cancer Pancreatic Cancer UK, The Netherlands Research Consumer Forum NCRI Upper GI Executive Cancer Institute UK Group, NCRI Pancreatic The Netherlands 4 5 7 Cancer workstream Editions of Patient Days patient information sheets/ study concept reviews UK 84 informed consents received in 2020 Annual report 2020 ANNUAL REPORT Patient involvement guidance 2020

Guidance is in development to support EORTC Disease-Oriented Groups to actively involve patients and patient organisations in a systematic, consistent and sustainable way. It will offer practical advice with an overview of the key elements and challenges involved. The Guidance Clinical trial brochure is part of a toolkit, including some templates and relevant presentations. It is being developed by The patient panel thoroughly reviewed the EORTC the EORTC International Policies and Affairs unit in clinical trial brochure to improve its layout, consultation with experienced patient panel design and coherence. Their contributions will members. The Guidance will be finalised after help make the content more understandable and receiving input from the Disease-Oriented Groups. relatable for patients and their family members.

Group survey Risk assessment of patient data Patient panel’s Chair co-developed a survey with EORTC HQ to identify the limits and OUR POLICY opportunities for patient involvement in In 2020 we had an unique opportunity to benefit Groups. The results of the survey should contribute from patient contributions not only in research to pragmatic solutions tailored to the needs of but also to data protection related matters. When each Group and will be included in the forthcoming developing a standard operation procedure on ACTIONS IN Patient Involvement Guidance. the Data Protection Impact Assessment, we asked the patient panel to review different scenarios involving the processing of patient data in clinical research and to evaluate the related risks. 2020 During this exercise, we noticed that patients actually upgraded the risk levels that researchers had defined. This suggests that they may be more vigilant to data inaccuracy and unauthorised access to their data than researchers. It also revealed that the spectrum of patient contributions is quite broad and should not be limited to clinical 86 studies. Annual report 2020

Treatment optimisation

Making treatment optimisation a mandatory step in treatment access was the central theme of our policy actions in 2020. EORTC shares the widespread concern that approved expensive new drugs may not provide substantial added benefit to patients.

Advocacy began in the European Parliament Europe’s Beating in 2019 with the launch of the manifesto for institutional communication, there remains no Cancer Plan treatment optimisation co-ordinated by concrete action to date. EORTC. The manifesto includes specific policy recommendations to produce cost savings that To drive action forward in 2020, we focused can enhance access to innovative treatments on awareness-raising with influential The EORTC was actively engaged in consultations across Europe, including: stakeholders, meeting with MEPs including: in 2020 on Europe’s Beating Cancer Plan. Presented Véronique Trillet-Lenoir, Petra De Sutter, Peter in February 2020, the Plan is the EU’s response to Complimenting regulatory clinical trials to identify Liese and Frédérique Ries. We are continuing growing challenges and developments in cancer and qualify new agents with independent clinical cross talks with the European Medicine Agency control. research on the optimal use of drugs, including on and Health Technology Assessment bodies such the duration, dosage and combination with other EUnetHTA and IQWIG. We are also now in contact Our advocacy focused on promoting patient- therapies. with payers including the BeNeLuxA Member centric independent clinical research in oncology States Initiative. and ensuring sufficient public funding to Funding for optimisation studies that collect make academic research including treatment real-world data in a controlled clinical environment Since this policy challenge is not limited to optimisation a reality in Europe. to help close the so-called efficacy-effectiveness oncology, we are in talks with the BioMed Alliance gap. to form an umbrella group with other disease areas such as respiratory disease. We started Making continuity from drug registration into discussions as well with the pharmaceutical and healthcare research mandatory. medical device working group of the Organisation for Economic Co-operation and Development Many stakeholders have joined in supporting (OECD). the manifesto, such as Members of the European Parliament, patient organisations, scientific We also advocated for treatment optimisation societies, biotechnology and pharmaceutical during official consultations on the EU’s industry representatives. Although we have seen Pharmaceutical Strategy for Europe, adopted on greater mentions of treatment optimisation in EU 25 November 2020.

88 89 General Data EU-funded projects in Protection Regulation 2020 (GDPR)

Since coming into force in 2018, the European Despite the pandemic, 2020 was a busy using real-world data to validate the benefit General Data Protection Regulation (GDPR) year for EU-funded projects. EORTC of proton therapy in Head and Neck cancer. has been causing significant concern amongst carried on the coordination of “Integrated HTx is also an opportunity to investigate how the scientific community for its impact on the Immunoprofiling of large adaptive Cancer research organisations like EORTC can support collection and use of data in clinical research. patient cohorts” (IMMUcan). The project aims health technology assessments. This is in line In 2020, the EORTC raised concerns with to understand the tumour micro-environment with EORTC’s policy actions around treatment policymakers regarding: and how it evolves under the influence of cancer optimisation. treatment using tumour samples from some Diverging national implementation and the 3.000 cancer patients combined with clinical data. Finally, we signed a grant agreement with uncertainty regarding the correct compliance the EU Innovative Medicines Initiative with its provisions. The fully integrated project pipeline is now for “Setting International Standards of operational. Access to patient material has been Patient-Reported Outcomes and Quality Perceived barriers for longer storage and a significant challenge, exacerbated by Covid-19 of Life Endpoints in Cancer Clinical Trials” reuse of collected data as well as sharing of data restrictions. We are looking for additional clinical (SISAQOL-IMI). Co-ordinated by EORTC, SISAQOL- with other researchers. sites and research groups to participate outside IMI will establish guidance on how to use patient- EORTC. reported outcomes in cancer clinical trials. Started GDPR’s interplay with other European in January 2021, the project involves a large group legislation applicable to health research, EORTC is participating in a true multi-stakeholder of stakeholders including academic institutions, such as the Clinical Trials Regulation, In Vitro project to bridge the efficacy-effectiveness gap: industry, patient groups, regulatory agencies, HTA Diagnostic Medical Devices Regulation and Next Generation Health Technology Assessment and scientific societies from around the world. Medical Devices Regulation. (HTx). In collaboration with the European Proton Therapy Network, we are conducting a case study Complexities due to the application of Member State legislation on other matters, such as biobanks, registries and genetic testing.

90 91 ANNUAL Fellowships REPORT In 1991, we established the EORTC Fellowship research. It is also a chance to use EORTC’s Programme to encourage physicians, statisticians rich databases to work on practice-changing 2020 and scientists from around the world to engage in publications. European clinical cancer research. Whilst we are grateful to all our supporters Selected fellows work for up to three years at worldwide, we are especially appreciative of the EORTC headquarters in Brussels, the capital contributions from Belgian-based organisations. of Europe. It is a unique opportunity to absorb all aspects of creating, activating and bringing This includes Kom Op tegen Kanker for their cancer clinical research projects to maturity, from support to the Emmanuel van der Schueren the inside. fellowship, and the European Society for Paediatric Oncology (SIOPE) and Fonds Cancer Fellows are exposed to a range of training to (FOCA) for their continued support of the medical reinforce and expand their knowledge of clinical doctors’ fellowship.

Fellowship Fellows in 2020 achievements 23 fellowships ongoing 199 fellows sponsored 3 fellowships were awarded this 41 nationalities welcomed year (2 statisticians and 1 medical doctor)

Welcomed the world to EORTC headquarters EUROPE: Belgium, France, United Kingdom, Germany, Greece, Italy & The Netherlands AFRICA: Cameroon, Ghana, Morocco, Nigeria & Zimbabwe FELLOWSHIPS MIDDLE EAST: Saudi Arabia & Iran ASIA: Japan OCEANIA: Australia LATIN AMERICA: Brazil

92 93 Testimonials

I joined EORTC in 2018 right after graduation because “I believed a fellowship in biostatistics was the right next step for my career. Three years later, I couldn't be happier with my choice. EORTC has I’m focused on Radiotherapy EORTC Fellowships aren’t and prognostic models. It’s an given me the opportunity Quality Assurance (RTQA) “about solo research. They’re an exciting area with tremendous to work on - and even lead “in recently closed clinical opportunity to join a community untapped potential in radiation - important projects with trials in my Emmanuel van of researchers inspired by a oncology. Another project international collaborative der Schueren fellowship. shared mission. Group success involves developing and groups alongside extremely Since 1982, RTQA has been is considered an EORTC success. validating a predictive model competent senior colleagues. an essential component of People are open to new ideas for radiotherapy-induced EORTC radiotherapy clinical and give you a platform to learn side effects. Both projects trials. It ensures that radiation and grow in projects that align are contributing to important therapy is safe and follows Nicolas Sauvé (France) with your interests - no matter advancements in patient joined the EORTC in April 2018. He trial protocols. It also helps holds the equivalent of a MSc degree your educational background. survival and quality of life. and is specialised in biostatistics. to improve toxicity profiles and disease control as well as In one project, I collaborated radiotherapy standards. with world-class artificial Marjan Sharabiani (Iran) intelligence experts to apply joined the EORTC in December 2018 as a medical physics fellow. She the technology to diagnostic holds a MSc in physics. Najlaa Alyamani (Saudi Arabia) joined the EORTC in May 2020. She holds a medical degree from King Saud University.

94 95 ANNUAL Events and campaigns REPORT 2020

The pandemic challenged us to convert the physical meetings that EORTC is world renowned for into virtual ones that could still deliver impact and allow for meaningful engagement. Our team rose to this challenge with impressive skill, welcoming over 6 500 delegates in 2020 from more than 100 countries to virtual conferences and Group meetings. This is a threefold increase from our average.

Post-event surveys revealed that the majority of delegates still prefer physical meetings as they miss networking with peers. Since we believe that a virtual component to meetings is here to stay, expect more hybrid events in the future.

EVENTS AND CAMPAIGNS

96 Annual report 2020 Events and campaigns

12th European Breast Cancer Conference Disciplines 25% Surgical Oncologist (EBCC 12) / General Surgeon 2-3 October 2020 3% Nurse Oncology / RT Technician 3% The European Breast Cancer Conference (EBCC) Industry - Scientist provides a unique multidisciplinary setting for all 3% EBCCouncil Patient Advocate / Representative professionals with a common interest in breast EBCC European Breast Cancer cancer to discuss, debate, inform and educate Conference VIRTUAL 5% themselves about this evolving disease. As Media (Broadcast/Print/Online)

the largest conference of its kind outside the US, aloni a 15% Ca t f o t r A

f

o Medical (1914 ) European Breast Cancer - October 5% Museum randina

G Gynaecologist a Oncologist the EBCC brings together diverse stakeholders from ional Na t Camara s elona Conference   ar c nglada A de B ació

clinicians and scientists to patient representatives Hermen © Dipu t 6% Radiotherapist/ Radiation from around the world. Oncologist 6% 12% Hosted virtually in 2020, we welcomed an multidisciplinary research. They also discussed Student Clinical Oncologist impressive 2 439 delegates from over 80 countries the impact of Covid-19 on clinical studies and to the 12th edition of the conference. Delegates how researchers can prepare for and respond to explored tangible advances made in prevention, pandemics and other crises in future. diagnosis, treatment and survivorship driven by Institutions 3% Cancer Research Centre 14% The Netherlands 4% TOP 10 countries University 7% Italy 5% Non-Profit Organisation 5% China 7% Cancer Centre 5% Spain 7% 5% Other Switzerland 49% 5% Hospital Argentina 5% United Kingdom 12% Industry 4% Belgium

4% Germany 3% 13% 98 USA University Hospital 99 Annual report 2020 Events and campaigns

Innovation and Methods in Clinical Biomarkers in Cancer Cancer Research Drug Development Workshop: virtual 2020 version 23 October 2020 postponed to November 2021 The annual Methods in Clinical Cancer Research multidisciplinary participants across 18 tumour IBCD 2020 32nd EORTC-NCI-AACR Workshop is a week-long course to educate types. It was decided not to hold a weeklong Innovation and Biomarkers in Cancer Drug Development and train early-career investigators in the best course instead one virtual session per protocol 23 October 2020 Symposium on practices of clinical trial design and provide access development group was organised. Faculty Under the auspices of Molecular Targets and to experienced clinical investigators from different members provided advice and recommendations institutions with expertise across all areas of to investigators in eight protocol development The Innovation and Biomarkers in Cancer Drug Cancer Therapeutics clinical research. The workshop is organized by the groups. Despite the virtual format, the workshop Development (IBCD) conference explores 24-25 October 2020 EORTC, ESMO and AACR and has provided training still enabled the peer-to-peer and mentoring the constantly evolving scientific, methodological to over 1 600 investigators from all over the world relationships that are core to the experience. and regulatory environment for drug and since its inception in 1999. biomarker development. It is organised by EORTC, Applications will open in May 2021 for NCI, EMA, and AACR with the involvement of FDA The symposium is a drug development and In 2020, we received 132 applications from 30 the next edition planned for November in Sint and PMDA. translational research meeting focusing on countries, of which 42 investigators were selected Michielsgestel in The Netherlands. preclinical and phase I studies. Hosted by from 12 countries. The workshop attracted In 2020, more than 400 delegates from the EORTC together with the National Cancer 52 countries came together for the virtual Institute (NCI) and the American Association for conference. Delegates explored topics including Attracting multidisciplinary Cancer Research (AACR), it enables and facilitates investigators comparative effectiveness in research and the in-depth scientific discussions on the latest translation of findings from clinical trials to daily developments in targets and drugs. 1 practice. Panel discussions also covered emerging Thoracic Oncology Radiation4 Oncology regulatory routes to approve new anti-cancer In this 32nd edition, we virtually welcomed 3 778 agents based on biomarkers. Presentations academics, scientists, industry representatives Pharmacy1 demonstrated the relevance and feasibility of and other experts from diverse disciplines. innovative clinical trial designs. Delegates explored the latest innovations in drug Pediatric2 Oncology development, target selection and the impact of new discoveries in molecular biology. Digestive1 Oncology

Clinical4 Oncology

Hematology1 Oncology

28Medical Oncology 100 101 Annual report 2020 Events and campaigns

Representing 18 tumour types Breast Cancer Movember 1 9 Awareness Month November Adult Non Hodgkin Lymphoma Breast Cancer Bladder Cancer Leukemia October Lung Cancer Melanoma Neuro Endocrine Tumour Ovarian Cancer Paediatric Brain Tumours Prostate Cancer Breast Cancer Awareness Month plays a vital Renal Cell Carcinoma Soft tissue Sarcoma role in increasing attention and support for the awareness, early detection, treatment and palliative care of the disease. Typically, we would host a series of events at our HQ, but due to the pandemic we co-hosted a webinar with the Breast International Group (BIG).

The webinar focused on the growing importance of Movember is an annual campaign that challenges treatment de-escalation to improve patient quality 4 men to grow moustaches during the month of Non Small Lung 6 of life by avoiding unnecessary overtreatment. Cancer Solid Tumours November to raise awareness about major health It was open to the general public – not just issues facing men: prostate cancer, testicular the scientific community – and engaged nearly 170 cancer and men’s suicide. Proceeds from 3 participants from around the world. Pancreatic Cancer the month-wide fundraiser go towards innovative research and projects that benefit men’s health around the world. 4 4 Head and Neck Cancer Colorectal cancer 3 Brain Tumour

World Cancer Day 4 February In 2020, EORTC staff sported their moustaches whilst working from home to support the cause. Despite confinement, staff raised nearly 1 300 € The global cancer community commemorates In support of the campaign in 2020, we published from the EORTC community for the Movember World Cancer Day on February 4 each year with a series of videos featuring members and staff Foundation. We also organised two well-attended the slogan ''I Am and I Will". EORTC has long highlighting the vital role of clinical research in webinars: one on prostate cancer and quality of supported the campaign, calling everyone, the global fight against cancer. The videos life and another on the future of genito-urinary collectively and individually, to commit to generated an impressive 1 500 views on social cancers in clinical research. strengthen actions to reduce the impact of cancer. media.

Visit our social channels with #IamAndIwill to 102 watch the videos. 103 ANNUAL 2020 Financial overview REPORT Total revenue in the 2020 fiscal year: 2020 Consolidated figures (EORTC, ECRF, FRIENDS OF EORTC, FFRTC)

9% Income 2020 Grants Industry (Regulatory Trials) We raised 5% Subsidies 1% € 41.7M Events for clinical cancer research 19% Royalties € 2.7M for operating expenses 10% Restricted & Unrestricted 44.4M Grants

We invested € 34.8 M 56% in clinical cancer research Grants Industry (Investigator Initiated Trials) € 0.6 M in education/fellowships € 0.9 M Expenditure 2020 2% in development, communication & Fellowships, Training, Education professional events 1% 2% Financials & Taxes € 4.8 M Office 2020 FINANCIAL in operating expenses % 1% 2 Development (taxes, administration, HQ) Communication & Events 19% Administration

OVERVIEW 41.1M

Net assets € 73.2 M in 2020 € 69.5 M in 2019 104 84% Research projects ANNUAL REPORT 2020

EORTC  CANCER RESEARCH FUND EORTC Cancer Research Fund 106 107 The EORTC Cancer Research Fund (ECRF) is an The grants and donations that power our work independent non-profit association founded in come from a diverse range of supporters, from OUR 2020 BOARD 1976 under the honorary presidency of the late institutions and foundations to the private sector Prince Philip, Duke of Edinburgh. ECRF’s mission and generous individuals across Europe and is to promote, encourage and support research around the world. on the treatment of cancer under the auspices of ECRF Trustees ECRF Advisory Board the EORTC. Victoria Agnew UK John Smyth (Prof) UK Diego du Monceau BE Jean Claude Horiot (Prof) CH Over the past 44 years, the ECRF has raised Guy Beniada FR Alexandre Eggermont (Prof) FR millions of euros to fund EORTC trials and projects Edward Chandler Oscar Lewisohn to develop new treatments and care that have UK UK increased survival and quality of life for cancer Prince Guillaume of Luxembourg LUX Lady Solti UK patients. Evelyne Genta UK Susanne Schroder UK Denis Lacombe BE Cigdem Simavi TU Marc Leland UK Daisy Pictet-Althann CH Sally Lo HK Robert Waley Cohen UK Gordon McVie (Prof) UK Jean-Leopold Schuybroek BE MESSAGE FROM Roger Stupp (Prof) US Jean de Gunzburg UK Alejandra MacCrohon-Gardner SP THE CHAIRMAN Suzan Sabanci-Dincer TUR

Due to Covid-19, our planned fundraising events The need to deliver high-quality and impactful had to be cancelled, postponed or where possible, clinical research for the benefit of cancer patients moved to an online format. remains the same if not more urgent today. With experts predicting a rise in cancer cases in future, With the invaluable support of our existing we need to power forward with research that can partners, we were able to continue supporting alleviate this burden for the millions of people EORTC’s important clinical research and welcome at-risk worldwide. new partners that share our values and mission in driving change for unmet scientific needs for Count Diego du Monceau de the benefit of cancer patients across the world. Bergendal Chairman of the fund

ECRF Board of Trustees (Board Meeting in Brussels) from left to right: HRH Prince Guillaume of Luxembourg, Mrs Alejandra 108 Mac-Crohon Gardner, Dr John Smyth, Count Diego du Monceau ECRF Chairman, Mrs Victoria Agnew, Mr Oscar Lewisohn 109 TOTAL RESTRICTED & 2020 HIGHLIGHTS UNRESTRICTED FUNDS RAISED PARTNERSHIP IN 2020

Consolidated figures (EORTC, ECRF, Friends of Precision oncology is the future of cancer treatment This pan-European platform allows for the rapid EORTC, Fondation Francaise RTC1) and with the Walgreens Boots Alliance (WBA), implementation of new clinical trials and robust we have made exciting leaps forward through translational cancer research. It helps guide the SPECTA platform. SPECTA is the leading patients’ treatments based on their own tumour infrastructure for translational clinical research for report analysis, diagnosed and confirmed by a all tumour types including rare cancers. group of leading international experts in the field. € 4.9M RESTRICTED & UNRESTRICTED GRANTS

66 WBA has worked in With SPECTA, the knowledge NUMBER OF ACADEMIC partnership with EORTC gained from addressing a PROJECTS FUNDED 2 “since 2011 to help fight “patient’s molecular biology (PARTIALLY & IN FULL) cancer. I’m very proud of the can now be extended to achievements we’ve made more cancers, enabling us to 23 together with SPECTA and the develop better treatments FELLOWSHIPS SPONSORED IN TOTAL impact of this collaboration across tumors. WBA’s on the ability of future support has catalysed these generations to survive this breakthroughs. 3 awful disease. NEW FELLOWSHIPS SPONSORED IN 2020 Richard Ellis Dr. Denis Lacombe Vice President of Corporate EORTC Director General. Social Responsibility, Walgreens Boots Alliance

1. Friends of EORTC & Fondation Francaise pour la Recherche et Traitement du Cancer110 (FFRTC) are registered charities in the UK and France respectively 111 2. No industry involvement SPECTA PLATFORM Despite the pandemic, In numbers WBA employees in 2020 continued to demonstrate their commitment to advance 1080+ EORTC’s mission for Patients adolescent and adult cancer patients. 17 countries

102 Investigators

625+ individual result reports to patients

112 December 31, 2020 113  EORTC Cancer Research Fund A NEW PARTNERSHIP WITH GENEROUSLY ENHANCING THE ANTICANCER FUND OUR CYBERSECURITY

In April 2020 the Anticancer Fund and EORTC announced a new partnership in support of the The EORTC deals with large volumes of patient data. Even though this data EORTC 1809 STRASS II trial in high-risk retroperitoneal is anonymised and complies with the strictest data protection standards, sarcoma, an aggressive and rare cancer affecting the no organisation can be fully immune to cybersecurity threats today. soft tissues of the body. Significant investments must be made to protect and defend IT ‘Securing research funding for areas with limited infrastructure. Thanks to the generous support of cybersecurity firm interest from the profit-driven cancer industry Advantio, EORTC’s infrastructure is now even more resilient and secure. is essential to complement progress’, explained The firm began donating their services in 2020 to enhance our security Lydie Meheus, managing director of the Anticancer posture. We are grateful for their continued defence of our mission. Fund. ‘By partnering with the EORTC, we have the leading organisation in clinical research in Europe that works together with industry but also tries to address other patient-centred needs in a non-profit way. Initiatives like this need encouragement’.

Belgian entrepreneur Filip Balcaen, a major donor to the Anticancer Fund, agrees. ‘I’m convinced that organisations should join forces to achieve major breakthroughs in the fight against cancer’, he It’s our great privilege to explained. provide our cybersecurity ‘We’re very pleased to partner with a like-minded “services to protect your organisation like the Anticancer Fund to address such an important question for patients with cancer-fighting mission high-risk retroperitoneal sarcoma’, said Dr. Denis Lacombe, Director General of the EORTC. ‘This marks the beginning of a successful partnership to Marco Borza tackle patient-centred questions where there is no CEO, Advantio industry involvement’. The total study cost amounts to approximatively €2.9M, of which €1.4M is already secured, the Anticancer Fund's financial contribution amounts to €700,000.

114 INVESTING IN THE WE NEED PARTNERS EDUCATION OF THE NEXT LIKE YOU GENERATION OF ONCOLOGY What is clinical PROFESSIONALS research exactly?

When you partner with the EORTC, you support A typical area of academic clinical research is Since 1991, the ECRF has supported the EORTC’s Fondation Contre le Cancer, University of Leiden, patient-centred clinical research that improves the advancement and optimisation of already Fellowship programme which enables physicians, Japan Clinical Oncology Group and the Belgian survival and quality of life. But what is clinical existing therapies. Academic clinical trials may, statisticians and scientists from around the world National Lottery. research exactly? Let us explain. for instance, test how a combination of treatments to engage in world-class research for up to three (drugs, radiotherapy and surgery) could improve years at EORTC headquarters in Brussels. The ECRF-BAEF partnership provides scholarships Cancer clinical trials are research investigations treatment outcomes. Or they may apply registered that enable American scientific students to spend with volunteers who test new treatments. Scientists treatments in additional or less frequent In 2020, the number of fellowships at the EORTC a year at the EORTC in Brussels. and doctors are constantly seeking to develop indications. reached a total of 18 fellows. The programme innovative, more effective and less toxic treatments benefits from the longstanding support of to improve patient survival and quality of life. organisations including: Fonds Cancer (FOCA), European Society for Paediatric Oncology, Clinical trials are necessary to confirm the safety and effectiveness of new treatments as well as decide whether side effects are acceptable when weighed against benefits.

In cancer research, some clinical trials evaluate new drugs, whilst others optimise different therapeutic approaches including surgery, radiation therapy and combinations of drugs already on the market. As with any new drug or treatment, however, there may be risks as well as benefits. That’s why clinical trials are closely monitored and usually conducted in hospitals or through outpatient departments.

Academic clinical cancer research, refers to clinical research which is not funded by pharmaceutical or biotechnology companies for commercialisation, but by non-profit clinical research organisations to advance cancer research and treatment for the benefit of patients. 116 117 Fighting cancer with clinical research THANK YOU

Improving cancer survival requires independent No tumour is too rare to tackle at the EORTC. Our Fonds Cancer multidisciplinary research that leads to research is solution-driven for all types of cancers, (FOCA) breakthrough clinical trials. Clinical trials are regardless of their commercial value. We leave the most important step on the journey from no-one behind because ultimately, cancer touches laboratory findings to standard medical practice us all. If not directly, through our families, friends that benefits patients. and our countries’ healthcare budgets.

The EORTC is uniquely positioned to deliver on We need your help to power our progress forward this mission as the strongest cancer fighting and welcome you to join us on this journey. organisation in Europe. We operate on a scale Together, we can increase patient survival and that would be impossible at a national level with quality of life. a record of achievement dating back to 1962.

Contact us New website

We make it easy for businesses and individuals to support our mission. Take Help support practice changing the first step and reach out to our team to start a conversation today! cancer clinical research ENVELOPE [email protected] phone +32 2 774 15 26 Belgium UK France

globe-africa www.eortcresearchfund.org/ EORTC ECRF Friends of EORTC Foundation Française RTC IBAN: IBAN: IBAN: BE79 0682 4292 7433 (EUR) GB30 COUT 1800 0201 8843 FR76 30000 4009 3200 0100 65 (GBP) 3025 923 (EUR)

Rest of Europe & USA for EORTC Cancer Research Fund Transnational Giving Europe (TGE) King Baudouin Foundation US 119 ANNUAL Group / REPORT Task Force Title Authors Journal DOI Klein M, Drijver A, van den Bent M, Bromberg J, Hoang-Xuan Memory in low-grade glioma K., Taphoorn M, Reijneveld 2020 https://doi. patients treated with radiotherapy or J, Ben Hassel M, Vauleon E, Brain Tumours Neuro-oncology org/10.1093/ Temozolomide. A correlative analysis Eekers D, Tzuk-Shina, Lucas A, neuonc/noaa252 of EORTC study 22033-26033 Villa Freixa S, Golfinopoulos V, Gorlia T, Hottinger A, Stupp R, Baumert B. Le Rhun E, Weller M, Niclou Gender issues from the perspective S, Short S, Piil K, Florien B, https://doi. of healthcare professionals in Neuro- Brain Tumours Ruda Roberta, Theodorou M, Neuro-oncology org/10.1093/nop/ oncology: an EANO & EORTC Brain Brandsma D, van den Bent M, npz053 Tumor Group survey Dirven L. Jaeckle K., Ballman K, Van den Bent M, Giannini C, Galanis E, Brown P, Jenkins R, Cairncross CODEL: phase III study of RT, RT + G, Wick W, Weller M, Aldape K, https://doi. TMZ, or TMZ for newly diagnosed Brain Tumours Dixon J, Anderson K, Cerhan Neuro-oncology org/10.1093/ 1p/19q codeleted oligodendroglioma. J, Wefel J, Klein M, Grossman neuonc/noaa168 Analysis from the initial study design S, Schiff D, Raizer J, Dhermain F, Nordstrom D, Flynn P, Vogelbaum M.

Kessler T, Berberich A, Sadik A, Sahm F, Gorlia T, Meisner Methylome analyses of three C, Hoffmann D, Wick A, https://doi. glioblastoma cohorts reveal Kickingereder P, Rübmann P, Brain Tumours Cancer Medicine org/10.1002/ chemotherapy sensitivity markers Bendszus M, Opitz C, Weller cam4.3447 within DDR genes M, Van den Bent M, Stupp R, Winkler F, Brandes A, von Deimling A, Platten M, Wick W.

Schell M, Pflüger I, Brugnara G, Isensee F, Neuberger U, Validation of diffusion MRI Foltyn M, Kessler T, Sahm F, phenotypes for predicting response https://doi. Wick A, Nowosielski M, Heiland Brain Tumours to bevacizumab in recurrent Neuro-oncology org/10.1093/ S, Weller M, Platten M, Maier- glioblastoma: post-hoc analysis of the neuonc/noaa120 Hein K, Von Deimling A, van PUBLICATIONS EORTC-26101 trial den Bent M, Gorlia T, Wick W, Bendszus M, Kickingereder P.

2020 Kickingereder P, Brugnara Noninvasive Characterization of G, Hansen M, Nowosielski M, Tumor Angiogenesis and Oxygenation Pflüger M, Schell M, Isensee in Bevacizumab-treated Recurrent F, Foltyn M, Neuberger U, https://doi. Glioblastoma by Using Dynamic Brain Tumours Kessler T, Sahm F, Wick A, Radiology org/10.1148/ Susceptibility MRI: Secondary Heiland S, Weller M, Platten M, radiol.2020200978 Analysis of the European Organization von Deimling A, Maier-Hein K, for Research and Treatment of Cancer Ostergaard L, van den Bent M, 26101 Trial Gorlia T, Wick W, Bendzsus M.

120 Group / Group / Task Force Title Authors Journal DOI Task Force Title Authors Journal DOI Delaloge S, Piccart M, Rutgers A new measure of treatment effect E, Litiere S, Van'T Veer L, Cantagallo E, De Backer M, https://doi. EORTC in clinical trials involving competing Biometrical van den Berkmortel F, Brain Kicinski M, Ozenne B, Collette org/10.1002/ Headquarters risks based on generalized pairwise Journal E, Dudek-Peric A, Gil-Gil M, L, Legrand C, Buyse M, Peron J bimj.201900354 Standard Anthracycline Based Versus Gomez P, Hilbers F, Khalil Z, comparisons Docetaxel-Capecitabine in Early High Knox S, Kuemmel S, Kunz G, https://doi. Journal of Clinical Breast Cancer Clinical and/or Genomic Risk Breast Lesur A, Pierga JY, Ravdin P, org/10.1200/ Oncology https://doi. Cancer in the EORTC 10041/BIG 3-04 Rubio I, Saghatchian M, Smilde JCO.19.01371 EORTC Clinical research in Europe: who do Lacombe D, Golfinopoulos V, Journal of Cancer org/10.1016/j. MINDACT Phase III Trial T, Thompson A, Viale G, Zoppoli Headquarters we do all that for? Negrouk A, Tombal B Policy G, Vuylsteke P, Tryfonidis K, jcpo.2020.100217 Poncet C, Bogaerts J, Cardoso F, MINDACT Investigators and de Rojas T, Neven A, Towbin A, https://doi. Clinical research tools in pediatric the TRANSBIG Consortium. EORTC Carceller F, Bautista F, Riedl D, org/10.1007/ oncology: challenges and Springer Headquarters Sodergren S, Darlington AS, s10555-020- Jacob L, Witteveen A, Beumer opportunities Fernandez-Teijeiro A, Moreno L 09856-z I, Delahaye L, Wehkamp D, van den Akker J, Snel M, Chan https://doi. Controlling technical variation B, Floore A, Bakx N, Brinck G, Communications org/10.1038/ Breast Cancer amongst 6693 patient microarrays of Poncet C, Bogaerts J, Delorenzi Biology s42003-020-1111- the randomized MINDACT trial Views of European Drug Development https://www. M, Piccart M, Rutgers E, 1 EORTC Stakeholders on Treatment Saesen R, Lejeune S, Quaglio G, Frontiers in frontiersin.org/ Cardoso F, Speed T, Van'T Veer Headquarters Optimization and Its Potential for Use Lacombe D, Huys I Oncology articles/10.3389/ L, Glas A. in Decision-Making fphar.2020.00043 Olivier-Gougenheim L, Arfeuille Pediatric randomized trial EORTC C, Suciu S, Sirvent N, Plat G, https://doi. Children CLG 58951: Outcome for adolescent Hematological Ferster A, De Moerloose B, org/10.1002/ Leukemia population with acute lymphoblastic Oncology Past, current and future cancer Clinical and https://doi. Domenech C, Uyttebroeck A, hon.2791 EORTC Broes S, Saesen R, Lacombe D, leukemia clinical research collaborations: the Translational org/10.1111/ Rohrlich P, Cave H, Bertrand Y. Headquarters Huys I case of the EORTC Science cts.12863 Journal of Papadavid E, Scarisbrick J, Management of primary cutaneous the European https://doi. Cutaneous Ortiz Romero P, Guaglino P, lymphoma patients during COVID-19 Academy of org/10.1111/ Lymphoma Vermeer M, Knobler R, Stadler Cross-Border Access to Clinical Trials Lalova T, Padeanu C, Negrouk https://doi. pandemic: EORTC CLTF guidelines Dermatology and jdv.16593 EORTC Frontiers in R, Bagot M. in the EU: Exploratory study on needs A, Lacombe D, Geissler J, org/10.3389/ Venereology Headquarters Medicine and reality Klingmann I, Huys I. fmed.2020.585722 C Garbe, K Peris, E Soura, A M Forsea, A Hauschild, M Arenbergerova , M Bylaite, V Del Marmol, V Bataille, M The European Organisation for Thomas G, Eisenhauer E, Samimi, S Gandini, P Saiag, T K Research and Treatment of Cancer, Bristow R, Grau C, Hurkmans https://doi. EORTC European Journal Position Statement The evolving field Eigentler, A Lallas, I Zalaudek, State of Science in radiation oncology C, Ost P, Guckenberger M, org/10.1016/j. Journal of Headquarters of Cancer of Dermato-oncology and the role of C Lebbe, J-J Grob, C Hoeller, C and priorities for clinical trials Deutsch E, Lacombe D, Weber ejca.2020.02.050 the European https://doi. Cutaneous dermatologists: Position Paper of the Robert, B Dréno, P Arenberger, meeting report D. Academy of org/10.1111/ Lymphoma EADO, EADV and Task Forces, EDF, IDS, L Kandolf-Sekulovic, R Dermatology and jdv.16849 EBDV-UEMS and EORTC Cutaneous Kaufmann, J Malvehy, S Puig, Venereology Lymphoma Task Force U Leiter, S Ribero, E Papadavid, P Quaglino, M Bagot, S M John, First results of the EORTC-SPECTA/ Morfouace M, Stevovic A, M-A Richard, M Trakatelli, C https://doi. Arcagen study exploring the genomics Vinches M, Golfinopoulos V, Jin Salavastru, L Borradori, B EORTC org/10.1136/ of rare cancers in collaboration with D, Holmes O, Erlich R, Fayette J, ESMO Open Marinovic, A Enk, C Pincelli, D Headquarters esmoopen- the European reference network Croce S, Ray Coquard I, Girard Ioannides, C Paul, A J Stratigos 2020-001075 EURACAN N, Blay JY. Sharing of clinical trial data and https://doi. EORTC Broes S., Verbaanderd C, Frontiers in samples: The cancer patient org/10.3389/ Headquarters Casteels M, Lacombe D, Huys I. Oncology perspective fmed.2020.00033

Vinches M, Neven A, Fenwarth Survival prediction models since https://doi. http://dx.doi. BMC Medical Clinical research for patients with L, Terada M, Rossi G, Kelly EORTC liver transplantation - comparisons Kantidakis G, Putter H, Lancia org/10.1186/ EORTC British Medical org/10.1136/ Research cancer in palliative care: where we S, Peron J, Thomaso M, Headquarters between Cox models and machine C, De Boer J, Braat A, Fiocco M. s12874-020- Headquarters Journal (BMJ) bmjspcare- Methodology stand Groenvold M., learning techniques 01153-1 2019-002086 de Rojas T. Group / Group / Task Force Title Authors Journal DOI Task Force Title Authors Journal DOI

Using both clinical research and Xie W, Regan M, Buyse M, population-based cancer registry in Liu L, Neven A, Giusti F, https://doi. Halabi S, Kantoff P, Sartor EORTC Journal of Cancer Event-Free Survival, a Prostate- longterm research- a case study using Maraldo M, Meijnders P, Aurer I, org/10.1016/j. O, Soule H, Berry D, Clarke Headquarters Policy Specific Antigen–Based Composite EORTC trials and the Dutch national Fortpied C, Collette L, Visser O. jcpo.2020.100226 N, Collette L, D'Amico A, De End Point, Is Not a Surrogate for https://doi. cancer registry (IKNL) Genito-Urinary Abreu Lourenco R, Dignam J, Journal of Clinical Overall Survival in Men With Localized org/10.1200/ Cancers Eisenberger M, James N, Fizazi Oncology Guckenberger M, Lievens Y, Prostate Cancer Treated With JCO.19.03114 K, Gillessen S, Loriot L, Mottet Bouma A, Collette L, Dekker Radiation. J Clin Oncol 2020; 38 (26). N, Parukelar W, Sandler H, A, deSouza N, Dingemans https://doi.org/10.1200/JCO.19.03114 Characterization and classification https://doi. Spratt D, Sydes M, Tombal B, A.M., Fournier B, Hurkmans C, EORTC of oligometastatic disease: and Lancet Oncology, org/10.1016/ Williams S, Sweeney C. Lecouvet F, Meattini I, Mendez Headquarters ESTRO and EORTC consensus The S1470- Romero A, Ricardi U, Russell recommendation 2045(19)30718-1 N, Schanne D, Schorsetti M, Generalizability Assessment of Head https://doi.org/ Tombal B, Verellen D, Verfaillie Head & Neck Sharabiani M, Clementel E, Radiation and Neck Cancer NTCP Models Based 10.1016/j.radonc. C, Ost P. Cancers Andratschke N, Hurkmans C. Oncology on the TRIPOD Criteria 2020.02.013 Mir R, Kelly S, Xiao Y, Moore A, Clark C, Clementel E, Corning C, Ebert M, Hoskin Deroose C, Lecouvet F, Collette European Organ at risk delineation for clinical P, Hurkmans C, Ishikura S, https://doi.org/ L, Oprea-Lager D, Kunz W, https://doi. EORTC Radiotherapy and Journal of trials: A Global Harmonization Group Kristensen I, Kry S, Lehmann J, 10.1016/j.radonc. Impact of the COVID-19 Crisis on Bidaut L, Verhoeff J, Caramella org/10.1007/ Headquarters Oncology Imaging Nuclear Medicine consensus guideline Michalski J, Monti A, Nakamura 2020.05.038 Imaging in Oncological Trials C, Lopci E, Tombal B, de Geus- s00259-020- and Molecular M, Thompson K, Yang H, Oei LF, Fournier,L, Smits M, 04910-y Imaging Zubizarreta E, Andratschke N, deSouza N. Miles E. Baron F, Efficace F, Cannella L, Muus P, Trisolini S, Halkes Cisplatin and 5-fluorouracil with or Moehler M, Maderer A, Thuss- C, Fazi P, Vignetti M, Marie JP, without epidermal growth factor Patience PC, Brenner B, Meiler Impact of the type of anthracycline Chiusolo P, van der Velden W, receptor inhibition panitumumab J, Ettrich TJ, Hofheinz RD, https://doi.org/ and of stem cell transplantation in La Sala E, Vitolo U, Thomas https://doi. Gastrointestinal for patients with non-resectable, Al-Batran SE, Vogel A, Mueller Annals of American Journal 10.1016/j.annonc. Leukemia younger patients with acute myeloid X, Lefrere F, Di Raimondo org/10.1002/ Cancer advanced or metastatic oesophageal L, Lutz MP, Lordick F, Alsina M, Oncology of Hematology 2019.10.018 leukaemia: long-term follow up of a F, Bourhis JH, Specchia G, ajh.25795 squamous cell cancer: a prospective, Borchert K, Greil R, Eisterer W, phase III study Guimaraes JE, Allione B, open-label, randomised phase III AIO/ Schad A, Slotta-Huspenina J, Vrhovac R, Ferrara F, Stevens- EORTC trial (POWER) Van Cutsem E, Lorenzen S. Kroef M, Meert L, De Witte T, Willemze R, Amadori S, Suciu S.

Schmoll HJ, Stein A, Van Ramadan S, Suciu S, Stevens- Cutsem E, Price T, Hofheinz Pre- and Postoperative Capecitabine Kroef M, Willemze R, Amadori RD, Nordlinger B, Daisne JF, Without or With Oxaliplatin in Locally https://doi. Survival Improvement over Time of S, De Witte T, Löwenberg B, https://doi. Gastrointestinal Janssens J, Brenner B, Reinel Journal of Clinical Advanced Rectal Cancer: PETACC 6 org/10.1200/ Leukemia 960 s-AML Patients Included in 13 Muus P, LaBar B, Meert L, De Cancer org/10.3390/ Cancer H, Hollerbach S, Caca K, Fauth Oncology Trial by EORTC GITCG and ROG, AIO, JCO.20.01740 EORTC-GIMEMA-HOVON Trials Schaetzen G, Meloni G, Leone cancers12113334 F, Hannig CV, Zalcberg J, AGITG, BGDO, and FFCD G, Vignetti M, Marie JP, Lübbert Tebbutt N, Mauer M, Marreaud M, Baron F. S, Lutz M, Haustermans K. Peters S, Danson S, Hasan B, Dafni U, Reinmuth N, Majem M, Tournoy K, Mark M, Pless M, A Randomized Open-Label Phase Cobo M, Rodriguez D, Falchero VESTIGE: Adjuvant Immunotherapy in III Trial Evaluating the Addition of L, Moran T, Ortega AL, Monnet Patients With Resected Esophageal, Denosumab to Standard First-Line I, Mohorcic K, Massuti B, Gastroesophageal Junction Smyth E, Knoedler M, Giraut Treatment in Advanced NSCLC: Journal of https://doi. https://doi. Betticher D, Demedts I, Macias Gastrointestinal and Gastric Cancer Following A, Mauer M, Nilsson M, Van Frontiers in Lung Cancer The European Thoracic Oncology Thoracic org/10.1016/j. org/10.3389/ JA, Cuffe S, Luciani A, Garcia Cancer Preoperative Chemotherapy With Grieken N, Wagner AD, Moehler Oncology Platform (ETOP) and European Oncology jtho.2020.06.011 fonc.2019.01320 Sanchez J, Curioni A, Gautschi High Risk for Recurrence (N+ and/ M , Lordick F. Organisation for Research and O, Price G, Coate L, Von Moos or R1): An Open Label Randomized Treatment of Cancer (EORTC) R, Zielinski C, Provencio M, Controlled Phase-2-Study SPLENDOUR Trial Menis J, Ruepp B, Pochesci A, Roschitzki H, Besse B, Rabaglio M, O'Brien M, Stahel R. Group / Group / Task Force Title Authors Journal DOI Task Force Title Authors Journal DOI Eggermont A, Kicinski M, Blank Garbe C, Keim U, Suciu S, C, Mandala M, Long G, Atkinson Amaral T, Eigentler T, Gesierich Prognosis of Patients With Stage III Association Between Immune- V, Dalle S, Haydon A, Khattak A, Hauschild A, Heinzerling Melanoma According to American Related Adverse Events and A, Carlino M, Sandhu S, Larkin L, Kiecker F, Schadendorf D, https://doi. Joint Committee on Cancer Version Journal of Clinical Recurrence-Free Survival J, Puig S, Ascierto P, Rutkowski JAMA (Journal https://doi.org/ Melanoma Stadler R, Sunderkotter C, org/10.1200/ 8: A Reassessment on the Basis of Oncology Among Patients With Stage III P, Schadendorf D, Koornstra R, of the American 10.1001/ Tuting T, Uitikal J, Wollina JCO.19.03034 Melanoma 3 Independent Stage III Melanoma Melanoma Randomized to Receive Hernandez Aya L, Di Giacomo Medical jamaoncol. U, Zouboulis C, Keilholz U, Cohorts Pembrolizumab or Placebo A AM, Van den Eertwegh A, Association) 2019.5570 Testori A, Martus P, Leiter U, Secondary Analysis of a Randomized Grob JJ, Gutzmer R, Jamal R, Eggermont A. Clinical Trial Lorigan P, Krepler C, Ibrahim N, Marreaud S, van Akkooi A, Robert C, Suciu S. Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Evaluating the potential of relapse- Coart E, Suciu S, Squifflet https://doi. Bastholt L, Bataille V, Del free survival as a surrogate for overall P, Saad E, Moshyk A, de European Journal European consensus-based Marmol, Dreno B, Fargnoli MC, Melanoma org/10.1016/j. https://doi. survival in the adjuvant therapy of Schaetzen G, Buyse M, Weber of Cancer interdisciplinary guideline for Grob JJ, Holler C, Kaufmann European Journal ejca.2020.07.011 Melanoma org/10.1016/j. melanoma with checkpoint inhibitors J, Eggermont A, Kotapati S. melanoma. Part 2: Treatment Update R, Lallas A, Lebbe C, Malvehy of Cancer ejca.2019.11.015 2019 J, Middleton M, Moreno- Szumera-Ciećkiewicz A, Ramirez D, Pellacani G, Saiag P, Bosisio F, Teterycz P, Antoranz Stratigos A, Vieira R, Zalaudek "SOX10 is as specific as S100 protein in A, Delogu F, Koljenović S, I, Eggermont A. https://doi. detecting metastases of melanoma in van de Wiel BA, Blokx W, European Journal Melanoma org/10.1016/j. lymph nodes and is recommended for van Kempen LC, Rutkowski of Cancer ejca.2020.06.037 sentinel lymph node assessment" P, Christopher van Akkooi Garbe C, Amaral T, Peris K, A, Cook M, Massi D, EORTC Hauschild A, Arenberger P, Melanoma Group Bastholt L, Bataille V, Del European consensus-based Marmol V, Dreno B, Fargnoli https://doi. Verver D, Rekkas A, Garbe C, interdisciplinary guideline for MC, Grob JJ, Höller C, European Journal van Klaveren D, van Akkooi Melanoma org/10.1016/j. The EORTC-DeCOG nomogram melanoma. Part 1: Diagnostics – Kaufmann R, Lallas A, Lebbe of Cancer ACJ, Rutkowski P, Powell ejca.2019.11.014 adequately predicts outcomes of https://doi. Update 2019 C, Malvehy J, Middleton M, BWEM, Robert C, Testori A, European Journal Melanoma patients with sentinel node-positive org/10.1016/j. Moreno-Ramirez D, Pellacani van Leeuwen BL, van der Veldt of Cancer melanoma without the need for ejca.2020.04.022 G, Saiag P, Stratigos AJ, Vieira AAM, Keilholz U, Stadler R, completion lymph node dissection R, Zalaudek I, Eggermont A. Eggermont AMM, Verhoef C, Leiter U, Grünhagen DJ.

Eggermont A, Rutkowski P, Coens C, Pe M, Dueck AC., Adjuvant therapy with Pegylated Dutriaux C, Hoffman-Wellenhof Sloan J, Basch E, Calvert M, Interferon-alfa2b vs Observation R, Dziewulski P, Marples M, Campbell A, Cleeland C., in stage II B/C patients with Grange F, Lok C, Pennachioli https://doi. Cocks K, Collette L, Devlin N., European Journal Dorme L, Flechtner H, Gotay Melanoma ulcerated primary: results of the E, Robert C, van Akkoi A, org/10.1016/j. International standards for the of Cancer C, Griebsch I, Groenvold M., European Organisation for Research Bastholt L, Minisini A, Marshall ejca.2020.04.015 analysis of quality-of-life and patient- https://doi. Johnson L, King M, Kluetz P, and Treatment of Cancer 18081 E, Sales F, Grob JJ, Bechter O, reported outcome endpoints in Lancet Oncology, org/10.1016/ Quality of Life Koller M., Malone D, Martinelli randomised trial Schadendorf D, Marreaud S, cancer randomised controlled trials: The S1470- F, Mitchell S. , Musoro J., Kicinski M, Suciu S, Testori A. recommendations of the SISAQOL 2045(19)30790-9 O'Connor D, Oliver K, Piault- Consortium Louis E, Piccart M, Quinten C, Reijneveld J, Schürmann Eggermont A, Rutkowski P, C., Wilder Smith A, Soltys Dutriaux C, Hoffman-Wellenhof K, Sridhara R, Taphoorn M, Longer Follow-Up Confirms R, Dziewulski P, Marples M, Velikova G., Bottomley A. Recurrence-Free Survival Benefit of Grange F, Lok C, Pennachioli https://doi. Adjuvant Pembrolizumab in High- Journal of Clinical Melanoma E, Robert C, van Akkoi A, org/10.1200/ Results from a one-day workshop on Risk Stage III Melanoma: Updated Oncology Terada M, Nakamura K., Bastholt L, Minisini A, Marshall JCO.20.02110 the assessment of Quality of Life in Results From the EORTC 1325-MG/ Martinelli F, Pe M, Mizusawa Japanese Journal https://doi. E, Sales F, Grob JJ, Bechter O, cancer patients: A joint initiative of KEYNOTE-054 Trial Quality of Life J, Eba J, Fukuda H, Kiyota N, of Clinical org/10.1093/jjco/ Schadendorf D, Marreaud S, the Japan Clinical Oncology Group Gatellier L, Majima Y, Velikova Oncology hyaa119 Kicinski M, Suciu S, Testori A. and the European Organisation for G, Bottomley A. Research and Treatment of Cancer Group / Group / Task Force Title Authors Journal DOI Task Force Title Authors Journal DOI

Koller M, Shamieh O, Giesinger J, Blazeby J, Differences in Patient-Reported Hjermstad M, Hornslien K, Aaronson N, Sprangers M, Outcomes That Are Most Frequently https://doi. Young T, Chalk T, Ioannidis Fayers P, Sparano F, Rees J, Quality of Life Detected in Randomized Controlled Value in Health org/10.1016/j. G, Harle A, Johnson C, Anota A, Wan C, Pezold M, Psychometric properties of the Trials in Patients With Solid Tumors: A jval.2020.02.007 Tomaszewski K, Serpentini https://doi. Isharwal S, Cottone F, Efficace updated EORTC module for assessing Pooled Analysis of 229 Trials S, Pinto M, van der Weijst L, Lancet Oncology, org/10.1016/ F. Quality of Life quality of life in patients with lung Janssens A, Morag O, Chie The S1470- cancer (QLQ-LC29): an international, WC, Arraras J, Pompili C, 2045(20)30093-0 observational field study Sodergren S, Wheelwright Jungraithmayr W, Hechtner S, Fitzsimmons D, Efficace F, M, Katsochi D, Müller K, Sprangers M, Fayers P, Harle Gräfenstein L, Schulz C, A, Schmidt H, Bottomley A, https://doi. Developing Symptom Lists for People Bottomley A. Darlington AS, Benson C, Targeted org/10.1007/ Quality of Life with Cancer Treated with Targeted Bredart A, Hentschel L, Arraras Oncology s11523-020- Therapies Minimally important differences for Musoro J, Coens C, Singer S, JI, Ioannidis G, Leahy M, 00769-z interpreting European Organisation Tribius S, Oosting S, Groenvold Journal of the Lugowska I, Nicolatou-Galitis https://doi. for Research and Treatment for M, Simon C, Machiels JP, Sciences and O, Petranovic D, Rohde G, Quality of Life org/10.1002/ Cancer (EORTC) Quality of life Gregoire V, Velikova G, Cocks K, Specialities of the Golfinopoulos V, Johnson C. hed.26363 Questionnaire Core 30 scores in Sprangers M, Kim M, Bottomley Head & Neck patients with head and neck cancer A. Evaluating the use of the EORTC patient-reported outcome measures https://doi. WIntner L, Giesinger J, for improving inter-rater reliability of org/10.1186/ Musoro J, Sodergren S, Coens Quality of Life Sztankay M, Bottomley A, Trials Minimally important differences for CTCAE ratings in a mixed population s13063-020- C, Pochesci A, Terada M, King https://doi. Holzner B . interpreting the EORTC QLQ-C30 in Colorectal of cancer patients: study protocol for 04745-w Quality of Life M, Sprangers M, Groenvold M, org/10.1111/ patients with advanced colorectal Disease a randomized controlled trial Cocks K, Velikova G, Flechtner codi.15295 cancer treated with chemotherapy HH, Bottomley A. Bjelic-Radisic V, Cardoso F, Cameron D, Brain E, Kuljanic V, https://doi. Normative data for the EORTC Lehmann J, Giesinger J, Nolte Health and da Costa RA, Conroy T, Inwald org/10.1186/ An international update of the EORTC Quality of Life QLQ-C30 from the Austrian general S, Sztankay M, Wintner L, Liegl quality of life E, Serpentini S, Pinto M, Weis J, https://doi.org/ s12955-020- questionnaire for assessing quality of Annals of population G, Rose M, Holzner B. outcomes Quality of Life Morag, Lindviksmoen Astrup 10.1016/j.annonc. 01524-8 life in breast cancer patients: EORTC Oncology G, Tomaszweksi K, Pogoda K, 2019.10.027 QLQ-BR45 Sinai P, Aaronson N, Velikova G, Nolte S, Waldmann A, Liegl G, https://doi. Greimel E, Arraras J, Bottomley Updated EORTC QLQ-C30 general European Journal Quality of Life Petersen M, Groenvold M, Rose org/10.1016/j. A. population norm data for Germany of Cancer M. ejca.2020.06.002 Demystifying the estimand Fiero M, Pe M, Weinstock C, https://doi. https://doi. Gamper EM, King T, Norman R, framework: a case study using King-Kallimanis B, Komo S, Lancet Oncology, org/10.1016/ EORTC QLU‑C10D value sets for Quality of Life org/10.1007/ Quality of Life Quality of Life Efficace F, Cottone F, Holzner B, patient-reported outcomes in Keplin H, Gray S, Bottomley A, The S1470- Austria, Italy, and Poland Research s11136-020- Kemmler G. oncology Kluetz P, Sridhara R. 2045(20)30319-3 02536-z Minimally important differences for Koch M, Jensen Hjermstad M, Musoro J, Coens C, Greimel E, Tomaszewski P, Hornslien K, interpreting European Organisation Gender effects on quality of life and King M, Sprangers M, Nordin https://doi. Harle A, Arraras J, Morag O, http://dx.doi. for Research and Treatment of Cancer Gynecologic symptom burden in patients with lung Journal of Quality of Life A, Van Dorst E, Groenvold M, org/10.1016/j. Quality of Life Pompili C, Ioannidis G, Navarra org/10.21037/jtd- (EORTC) Quality of life Questionnaire Oncology cancer: results from a prospective, Thoracic Disease Cocks K, Velikova G, Flechtner ygyno.2020.09.007 C, Chie W, Johnson C, Bohrer T, 20-1054 core 30 scores in patients with ovarian cross-cultural, multi-center study H, Bottomley A. Janssens A, Kulis D, Bottomley cancer A, Schulz C, Zeman F, Koller M. Coomans M, Taphoorn M, Petersen M, Aaronson N, Aaronson N, Baumert B, van Conroy T, Costantini A, Measuring change in health- den Bent M, Bottomley A, International validation of the EORTC Giesinger J, Hammerlid E, https://doi. related quality of life: the impact of Brandes A, Chinot O, Coens C, https://doi. Quality of Life, CAT Core: a new adaptive instrument Holzner B, Johnson C, Kieffer org/10.1007/ different analytical methods on the Gorlia T, Herrlinger U, Keime- Neuro-oncology org/10.1093/nop/ Quality of Life Springer Brain Tumours for measuring core quality of life J, van Leeuwen M, Nolte S, s11136-020- interpretation of treatment effects in Guibert F, Malmstrom A, npaa033 domains in cancer Ramage J, Tomaszewski K, 02421-9 glioma patients Martinelli F, Stupp R, Talacchi Waldmann A, Young T, Zotti P, A, Weller M, Wick W, Reijneveld Groenvold M. J, Dirven L. Group / Group / Task Force Title Authors Journal DOI Task Force Title Authors Journal DOI Objective neurocognitive functioning and neurocognitive complaints in Activity and safety of the multi-target Schoeffski P, Le Cesne, Kasper Caramanna I, Bottomley A, patients with high-grade glioma: https://doi. tyrosine kinase inhibitor cabozantinib B, Papai Z, Blay JY, Italiano A, Quality of Life, Drijver J, Twisk J, van den Bent European Journal in patients with metastatic Benson C, Kopeckova K, Ali Evidence of cognitive awareness org/10.1016/j. https://doi. Brain Tumours M, Idbaih A, Wick W, Pe M, Klein of Cancer Soft Tissue & gastrointestinal stromal tumor after N, Dileo P, Menge F, Cousin S, European Journal from the European Organisation for ejca.2020.10.040 org/10.1016/j. M, Reijneveld J. Bone Sarcoma treatment with imatinib and sunitinib: Wardelmann E, Wozniak A, of Cancer Research and Treatment of Cancer ejca.2020.04.021 brain tumour clinical trials European Organization for Research Marreaud S, Litiere S, Zaffaroni and Treatment of Cancer Phase 2 trial F, Nzokirantevye A, Vanden Coomans M, Dirven L, 1317 "CaboGIST" Bempt I, Gelderblom H. Aaronson N, Baumert B, van Calculating the net clinical benefit den Bent M, Bottomley A, in neuro-oncology clinical trials Brandes A, Chinot O, Coens C, https://doi. Quality of Life, Neuro-Oncology using two methods: quality-adjusted Gorlia T, Herrlinger U, Keime- org/10.1093/ Bonvalot S, Gronchi A, Le Brain Tumours Advances survival effect sizes and joint Guibert F, Malmström A, noajnl/vdaa147 Pechoux C, Swallow C, Strauss modeling Martinelli F, Sloan J, Stupp R, Preoperative radiotherapy plus D, Meeus P, van Coevorden F, Talacchi A, Weller M, Wick W, surgery versus surgery alone for Stoldt S, Stoeckle E, Rutkowski https://doi. Reineveld J, Taphoorn M. Soft Tissue & patients with primary retroperitoneal P, Rastrelli M, Raut C, Hompes Lancet Oncology, org/10.1016/ Bone Sarcoma sarcoma (EORTC-62092: STRASS): a D, De Paoli A, Sangalli C, The S1470- Poortmans P, Weltens multicentre, open-label, randomised, Honore C, Chung P, Miah A, Blay 2045(20)30446-0 C, Fortpied C, Kirkove C, phase 3 trial JY, Fiore M, Stelmes JJ, Dei Tos Peignaux-Casasnovas K, A, Baldini E, Litiere S, Marreaud Internal mammary and medial Budach V, van der Leij F, Vonk https://doi. S, Gelderblom H, Haas R. Radiation supraclavicular lymph node chain E, Weidner N, Rivera S, Van Lancet Oncology, org/10.1016/ Oncology, irradiation in stage I–III breast cancer Tienhoven G, Fourquet A, Noel The S1470- Breast Cancer (EORTC 22922/10925): 15-year results G, Valli MC, Guckenberger M, 2045(20)30472-1 of a randomised, phase 3 trial Koiter E, Racadot S, Abdah- Constantinidou A, Sauve N, Bortnyak R, Van Limbergen Stacchiotti S, Blay JY, Vincenzi https://doi.org/ E, Engelen A, De Brouwer P, Evaluation of the use and efficacy B, Grignani G, Rutkowski Soft Tissue & 10.1136/ Struikmans H, Bartelink H. of (neo)adjuvant chemotherapy in P, Guida M, Hindi N, Klein ESMO Open Bone Sarcoma esmoopen- angiosarcoma: a multicenter study A, Valentin T, Sufliarsky J, D'Ambrosio L., Touati N., Blay 2020-000787 Desar I, Steeghs N, Litiere S, J.Y., Grignani G., Filippot R. Gelderblom H, Jones R. Doxorubicin plus dacarbazine, , Czarnecka A., Pipperno- doxorubicin plus ifosfamide, Neuman S., Martin-Broto or doxorubicin alone as a first‐ J., Sanfilippo R. , Katz D., line treatment for advanced Duffaud F., Vincenzi B., Stark https://doi. Survival of soft tissue sarcoma Soft Tissue & Verschoor J, Litiere S, https://doi. leiomyosarcoma: A propensity score D., Mazzeo F., Tuchscherer A. , Cancer org/10.1002/ patients after completing six cycles Bone Sarcoma Soft Tissue & Marreaud S, Judson I, Clinical Sarcoma org/10.1186/ matching analysis from the European Chevreau C., Sherriff J., Estival cncr.32795 of first-line anthracycline containing Bone Sarcoma Toulmonde M, Wardelmann E, Research s13569-020- Organization for Research and A., Litiere S., Sents W., Ray treatment: an EORTC-STBSG Le Cesne A, Gelderblom H. 00137-5 Treatment of Cancer Soft Tissue and Coquard I, Tolomeo F, Le Cesne database study Bone Sarcoma Group A, Rutkowski P, Stacchiotti S. , Kasper B, Gelderblom H., Gronchi A. A randomized double-blind Ray-Coquard I, Hatcher Gronchi A, Bonvalot S, phase II study evaluating the role H, Bompas E, Casado A, Poveda Velasco A, Kotasek of maintenance therapy with Westermann A, Isambert N, International http://dx.doi. D, Rutkowski P, Hohenberger Soft Tissue & cabozantinib in high-grade uterine Casali P, Pratap S, Stark D, Journal of org/10.1136/ijgc- Quality of Surgery and Outcome P, Fumagalli E, Judson I, Bone Sarcoma sarcoma after stabilization or Valverde C, Anand A, Huizing M, Gynecological JAMA (Journal https://doi.org/ 2020-001519 in Localized Gastrointestinal Italiano A, Gelderblom H, Van response to doxorubicin ± ifosfamide Floquet A, Lindner L, Hermes Cancer Soft Tissue & of the American 10.1001/ Stromal Tumors Treated Within an Coevorden F, Penel , Kopp following surgery or in metastatic first B, Seddon B, Coens C, Jones R, Bone Sarcoma Medical jamasurg. International Intergroup Randomized H, Duffaud F, Goldstein D, line treatment (EORTC62113) Reed N. Association) 2020.0397 Clinical Trial of Adjuvant Imatinib Martin-Broto J., Wardelmann E, Marreaud S, Smithers M, Le Cesne A, Zaffaroni F, Litiere S, Impact of acute kidney injury on Blay J.Y., Casali P. anticancer treatment dosage and Peron J, Neven A, Collette L, Nephrology https://doi. Soft Tissue & long-term outcomes: a pooled https://doi. Launay-Vacher V, Sprangers B, Dialysis org/10.1093/ndt/ iCREATE: Imaging features of primary Mcaddy N, Saffar H, Litiere Canadian Bone Sarcoma analysis of European Organisation for Soft Tissue & org/10.1186/ Marreaud S. Transplantation gfaa049 and metastatic alveolar soft part S, Jespers P, Schoeffski P, Journal of Research and Treatment of Cancer Bone Sarcoma s40644-020- sarcoma in the EORTC CREATE study Messiou C. Gastroenterology trials 00352-9 ANNUAL REPORT Primary Secondary Number Alias Title Status Group Groups

SPECTA: Screening Cancer Patients for 1553 SPECTA Recruiting 2020 Efficient Clinical Trial Access

A randomized trial of Adryamicin (A) Cisplatin (P) chemotherapy versus Paclitaxel (T) Adriamycin LT-FU 55984 (A) and Cisplatin (P) in patients ongoing with metastatic/relapsed or locally advanced inoperable endometrial cancer.

EORTC Brain Tumor Group,EORTC Radiation Radiation versus Observation Oncology Group,Trans- following surgical resection of Atypical EORTC Brain Tasman Radiation 1308 ROAM Recruiting Meningioma: a randomised controlled Tumor Group Oncology Group Inc,Cancer trial (The ROAM trial) / EORTC 1308 Trials Ireland / ICORG,The Walton Centre NHS Foundation Trust

Trabectedin for recurrent grade II or Closed to EORTC Brain 1320 III meningioma: a randomized phase II EORTC Brain Tumor Group Patient Entry Tumor Group study of the EORTC Brain Tumor Group

INTELLANCE 2: ABT 414 alone or ABT 414 plus temozolomide versus INTELLANCE lomustine or temozolomide for Closed to EORTC Brain 1410 EORTC Brain Tumor Group 2 recurrent glioblastoma: a randomized Patient Entry Tumor Group phase II study of the EORTC Brain CLINICAL Tumor Group Evaluation of ABT-414 in Children with High Grade Gliomas (Main study: ABT-414 alone or ABT-414 plus Pediatric Sub Closed to EORTC Brain 1410p temozolomide versus lomustine for EORTC Brain Tumor Group 1410-BTG Patient Entry Tumor Group recurrent glioblastoma: a randomized TRIALS phase II study of the EORTC Brain Tumor Group)

Molecular genetic, host-derived and EORTC Brain Tumor EORTC Brain 1419 ETERNITY clinical determinants of long-term Recruiting Group,Brain Tumor Tumor Group 2020 survival in glioblastoma Funders' Collaborative Study of TG02 in Elderly Newly Diagnosed or Adult Relapsed Patients EORTC Brain 1608 STEAM Recruiting EORTC Brain Tumor Group with Anaplastic Astrocytoma or Tumor Group Glioblastoma: A Phase Ib Study

EORTC Brain Tumor Personalized Risk-Adapted Therapy in Group,Cooperative Post-Pubertal Patients with Newly- Regulatory in EORTC Brain 1634 PersoMed-I Trials Group for Neuro- Diagnosed Medulloblastoma Process Tumor Group Oncology,German Neuro- (PersoMed-I) Oncology Working Group Primary Secondary Primary Secondary Number Alias Title Status Group Groups Number Alias Title Status Group Groups

IDH mutated 1p/19q intact lower EORTC Breast Cancer grade glioma following resection: Wait EORTC Brain Group,Breast International 1635 I-WOT Recruiting EORTC Brain Tumor Group Or Treat? Tumor Group MINDACT (Microarray In Node- Group,Gruppo Oncologico IWOT - A phase III study negative and 1 to 3 positive Italiano Ricercia lymph node Disease may Avoid Clinica,Borstkanker Chemo Therapy): A prospective, Onderzoeksgroup A phase III trial of marizomib randomized study comparing the LT-FU EORTC Breast Nederland,National Cancer 10041 MINDACT in combination with standard 70-gene signature with the common ongoing Cancer Group Research Institute - Breast temozolomide-based EORTC Brain Tumor clinicpathological criteria in selecting Cancer Group,West German radiochemotherapy versus Closed to EORTC Brain 1709 MIRAGE Group,Canadian Cancer patients for adjuvant chemotherapy Study Group,Grupo standard temozolomide-based Patient Entry Tumor Group Trials Group in breast cancer with 0 to 3 positive espanol de estudio, radiochemotherapy alone in patients nodes" tratamiento y otras with newly diagnosed glioblastoma - estrategias experimentales MIRAGE en tumores solidos,SI_IOL

EORTC Brain Tumor A randomised, multi-centre, open- Group,EORTC label, phase III study of adjuvant EORTC Breast Cancer Radiation Oncology lapatinib, trastuzumab, their LT-FU EORTC Breast 10071 ALTTO Group10,Breast European Phase III trial on concurrent Group,NCIC Clinical sequence and their combination in ongoing Cancer Group and adjuvant temozolomide Trial Group,Radiation Adjuvant Studies Team Closed to EORTC Brain patients with HER2/ErbB2 positive 26053 CATNON chemotherapy in non-1p/19q deleted Therapy Oncology Patient Entry Tumor Group primary breast cancer anaplastic glioma. The CATNON Group,Cancer Trials intergroup trial. Support Unit,Cooperative Trials Group for Neuro- Swedish Association of Oncology,University Breast Oncologists, EORTC College of London Breast Cancer Group, Clinical and biological Breast International characterization of Male Breast Group, Schweizerisches Cilengitide in subjects with newly Cancer : an international retrospective LT-FU EORTC Breast 10085 Male BC Arbeitsgemeinschaft diagnosed glioblastoma and EORTC, BIG and NABCG intergroup ongoing Cancer Group Klin. Krebsforschung, methylated MGMT promoter gene- a study (for the prospective part, please Borstkanker multicenter, open-label, controlled refer to 10085p) Onderzoeksgroup Phase III study, testing cilengitide in EORTC Brain Tumor LT-FU EORTC Brain Nederland, Cancer Trials 26071 CENTRIC combination with standard treatment Group,EORTC Radiation ongoing Tumor Group Ireland / ICORG (temozolomide with concomitant Oncology Group radiation therapy, followed by temozolomide maintenance therapy) Swedish Association of versus standard treatment alone Breast Oncologists, EORTC (CENTRIC) Breast Cancer Group, Breast International Group, Schweizerisches Phase III Intergroup Study of Arbeitsgemeinschaft Radiotherapy with Concomitant EORTC Brain Tumor Klin. Krebsforschung, and Adjuvant Temozolomide versus Closed to EORTC Brain Group,Cooperative Borstkanker 26081 CODEL Radiotherapy with Adjuvant PCV Patient Entry Tumor Group Trials Group for Neuro- Onderzoeksgroup Chemotherapy in Patients with 1p/19q Oncology,Alliance Clinical and biological Nederland, Cancer Trials Co-deleted Anaplastic Glioma or Low Prospective characterization of Male Breast Closed to EORTC Breast Ireland / ICORG, Grupo 10085p Grade Glioma male BC Cancer: an international EORTC, BIG, Patient Entry Cancer Group Latino Americano de TBCRC and NABCG intergroup study. Investigações Clínicas A Phase III Trial Evaluating the Role of em Oncologia / Latin Ovarian Function Suppression and American Cooperative the Role of Exemestane as Adjuvant EORTC Breast Cancer Oncology Group, Therapies for Premenopausal Women Group,International Translational Breast Cancer LT-FU EORTC Breast 10031 SOFT with Endocrine Responsive Breast Breast Cancer Study Research Consortium, ongoing Cancer Group Cancer tamoxifen versus ovarian Group,Oncology Site Hellenic Oncology function suppression + tamoxifen Management Organization Research Group,Hellenic versus ovarian function suppression + Cooperative Oncology exemestane. Group Primary Secondary Primary Secondary Number Alias Title Status Group Groups Number Alias Title Status Group Groups

A randomised, double-blind, parallel group, placebo-controlled multi- A randomized multicenter, double- centre blind, placebo-controlled comparison Phase III study to assess the efficacy of chemotherapy plus trastuzumab EORTC Breast Cancer and safety of olaparib versus placebo EORTC Breast Cancer plus placebo versus chemotherapy LT-FU EORTC Breast 10112 Aphinity Group,Breast International as Group, Breast International plus trastuzumab plus pertuzumab ongoing Cancer Group Closed to EORTC Breast Group 1324 Olympia adjuvant treatment in patients with Group, National Surgical as adjuvant therapy in patients with Patient Entry Cancer Group germline BRCA1/2 mutations and high Adjuvant Breast and Bowel operable HER2-positive primary risk Project breast cancer. HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy Phase III trial of radiation therapy vs no treatment for patients with in LT-FU EORTC Breast EORTC Breast Cancer 10853 situ ductal carcinoma of the breast Management of low grade ductal ongoing Cancer Group Group EORTC Breast Cancer (Jointly with the EORTC Radiotherapy carcinoma in situ (low-grade DCIS): Group, Borstkanker Cooperative Group) a randomized, multicenter, non- EORTC Breast 1401 LORD Recruiting Onderzoeksgroup inferiority trial, between standard Cancer Group Nederland, The Netherland therapy approach versus active Cancer Institute surveillance EORTC Breast Cancer Group, EORTC After Mapping of the Radiation Oncology LT-FU EORTC Breast EORTC Breast Cancer 10981 AMAROS Axilla:Radiotherapy Or Surgery Group, Borstkanker Aiming to Understand the MOlecular ongoing Cancer Group EORTC Breast Group,Breast International AMAROS Onderzoeksgroup 1408 AURORA Aberrations in Metastatic Breast Recruiting Cancer Group Group,International Breast Nederland, ALMANAC Cancer Trialists Group Cancer Study Group

A phase II study of Palbociclib plus Fulvestrant for pretreated patients Swedish Association of with ER+/HER2- metastatic Breast EORTC Breast Cancer Closed to EORTC Breast Breast Oncologists,EORTC 1502 PYTHIA Cancer; Palbociclib in molecularly Group,International Breast Patient Entry Cancer Group Breast Cancer characterized ER-Positive/HER2 Cancer Study Group Group,Breast International negative metastatic Breast Study: the Group,Grupo Espanol de PYTHIA study Investigacion del Cancer de Mama,International PALbociclib CoLlaborative Adjuvant Breast Cancer Study Study: A randomized phase III trial of EORTC Breast Cancer Group,Gruppo Oncologico palbociclib with adjuvant endocrine Italiano Ricercia Group,Breast International A phase III, randomized, open label, therapy versus endocrine therapy Closed to EORTC Breast Clinica,Borstkanker 1513 PALLAS Group,Austrian Breast and multicenter, controlled trial of alone for hormone receptor positive Patient Entry Cancer Group Onderzoeksgroup Colorectal Cancer Study niraparib versus physician’s choice in Closed to EORTC Breast (HR+)/ human epidermal growth 1307 BRAVO Nederland,Grupo espanol Group previously-treated, HER2 negative, Patient Entry Cancer Group factor receptor 2 (HER2)-negative de estudio, tratamiento germline BRCA mutation-positive early breast Cancer y otras estrategias breast cancer patients. experimentales en tumores EORTC Breast Cancer Selective Use of Postoperative solidos,Hellenic Oncology Closed to EORTC Breast Group,EORTC Radiation 22051 SUPREMO Radiotherapy AftEr MastectOmy Research Group,Hellenic Patient Entry Cancer Group Oncology Group22,Scottish (SUPREMO) Cooperative Oncology Cancer Trials Breast Group Group,Icelandic Breast Cancer Group,Institute Cancer in elderly nursing home of Cancer Research - residents in Belgium: prospective EORTC Cancer Clinical Trials & Statistics nursing cohort study including translational Closed to EORTC Cancer in Elderly 1221 in Elderly Task Unit,Sheba Breast home project research to develop better prognostic Patient Entry Task Force Force Collaborative Group tools to help with treatment decisions in the elderly Primary Secondary Primary Secondary Number Alias Title Status Group Groups Number Alias Title Status Group Groups The value of 1) Dexamethasone vs Swedish Association of prednisolone during induction 2) Breast Oncologists,EORTC of prolonged versus conventional Breast Cancer duration of L-Asparaginase EORTC Group,EORTC Cancer therapy during consolidation LT-FU Children's EORTC Children's Leukemia in Elderly Task 58951 and late intensification, in acute ongoing Leukemia Group Force,Breast International lymphoblastics leukemia and Group Group,International A Phase II study of Adjuvant lymphoblastic non-Hodgkin Breast Cancer Study PALbociclib as an Alternative to EORTC Cancer lymphoma of childhood. A Group,Gruppo 1745 APPALACHES CHemotherapy in Elderly patientS Recruiting in Elderly Task Randomised phase III study. Oncologico Italiano with high-risk ER+/HER2- early breast Force Ricercia Clinica,German cancer (APPALACHES) Assessment of the long term outcome EORTC Adjuvant Breast Cancer of childhood ALL patients enrolled in Closed to Children's EORTC Children's Leukemia 58LAE Group,Grupo espanol EORTC CLG trials between 1971 and Patient Entry Leukemia Group de estudio, tratamiento 1998 Group y otras estrategias experimentales en Study to determine the aetiology EORTC tumores solidos,Unicancer of chlormethine gel induced-skin Regulatory in Cutaneous EORTC Cutaneous Oncogeriatrics Group 1754 REACH drug reaction in early stage mycosis Process Lymphoma Lymphoma Task Force fungoides cutaneous T cell lymphoma Task Force (MF-CTCL) Pertuzumab + trastuzumab (PH) versus PH plus metronomic Open-Label, phase II, Multi-Center, chemotherapy (PHM) in the elderly study of Anti-CCR4 Monoclonal EORTC HER2+ metastatic breast cancer Swedish Association of Antibody (mogamulizumab) Plus Total Regulatory in Cutaneous EORTC Cutaneous population who may continue on EORTC Cancer Breast Oncologists,EORTC 1820 MOGAT LT-FU Skin Electron Beam therapy (TSEB) in Process Lymphoma Lymphoma Task Force 75111 T-DM1 alone following disease in Elderly Task Breast Cancer ongoing patients with stage IB-IIB Cutaneous Task Force progression while on PH/PHM: an Force Group,EORTC Cancer in T-Cell Lymphoma (MOGAT) open-label multicentre randomized Elderly Task Force phase II selection trial of the EORTC Phase II trial of atezolizumab (anti- EORTC Elderly Task Force and Breast Cancer PD-L1) in the treatment of stage IIb-IV Closed to Cutaneous EORTC Cutaneous Group 1652 PARCT mycosis fungoides/sezary syndrome Patient Entry Lymphoma Lymphoma Task Force patients relapsed/refractory after a Task Force EORTC Children's previous systemic treatment International collaborative treatment EORTC Leukemia Group,French protocol for infants under one Closed to Children's 58051 Interfant Acute Lymphoblastic A phase II study exploring the safety year with acute lymphoblastic or Patient Entry Leukemia and efficacy of nintedanib (BIBF1120) Leukemia,Operating Center EORTC biphenotypic leukemia Group as second line therapy for patients Closed to EORTC Endocrine Tumors for Research and Statistics 1209 Endocrine with either differentiated or medullary Patient Entry Group Tumors Group Translational research - observational thyroid cancer progressing after first EORTC study for identification of new line therapy. Closed to Children's EORTC Children's Leukemia 58081 possible prognostic factors and future Patient Entry Leukemia Group therapeutic targets in children with Protocol SAKK 41/13 Adjuvant aspirin Group EORTC acute lymphoblastic leukaemia (ALL). treatment in PIK3CA mutated colon Closed to Gastrointestinal 1534 cancer patients. A randomized, Patient Entry Tract Cancer double-blinded, placebo-controlled, International Study for Treatment of Group phase III trial Standard Risk Childhood Relapsed ALL EORTC EORTC Children's IntReALL SR 2010. A randomized Phase III Study Closed to Children's Leukemia Group,Charite 58111 2010 Conducted by the Resistant Disease Patient Entry Leukemia Universitaetsmedizin INtegratioN of trastuzumab, with EORTC EORTC Gastrointestinal Committee of the International BFM Group Berlin or without pertuzumab, into Gastrointestinal Tract Cancer Group,Korean Study Group 1203 INNOVATION periOperatiVe chemotherApy of Recruiting Tract Cancer Cancer Study Group,Dutch HER-2 posiTIve stOmach caNcer: the Group Upper GI Group INNOVATION-TRIAL

Randomized phase III study EORTC EORTC EORTC Gastrointestinal A prospective Colorectal Liver comparing IDA versus MTZ in LT-FU Children's EORTC Children's Leukemia Closed to Gastrointestinal Tract Cancer 58921 1409 CLIMB Metastasis DataBase with an induction and intensification ongoing Leukemia Group Patient Entry Tract Cancer Group,European Society of Integrated Quality Assurance program treatment of AML or MDS in children Group Group Surgical Oncology Primary Secondary Primary Secondary Number Alias Title Status Group Groups Number Alias Title Status Group Groups EORTC Gastrointestinal Randomized phase II trial evaluating DREAM: Diffusion-Weighted Magnetic EORTC Tract Cancer Group,EORTC the efficacy of FOLFOX alone, FOLFOX EORTC REsonance Imaging Assessment of Gastrointestinal Imaging Group,European plus bevacizumab and FOLFOX plus 1527 DREAM Recruiting Closed to Gastrointestinal EORTC Gastrointestinal Liver Metastasis to Improve Surgical Tract Cancer Society of Surgical 40091 BOS 2 panitumumab as perioperative Patient Entry Tract Cancer Tract Cancer Group Planning Group Oncology,Japan Clinical treatment in patients with resectable Group Oncology Group liver metastases from wild type KRAS Phase II of immunotherapy plus local EORTC and NRAS colorectal cancer tumour ablation (RFA or stereotactic Gastrointestinal EORTC Gastrointestinal 1560 ILOC Recruiting radiotherapy) in patients with Tract Cancer Tract Cancer Group EORTC Gastrointestinal colorectal cancer liver metastases Group Tract Cancer Group, An open-label, randomized phase III Grupo Espanol para Open-label first line, single-arm trial of cisplatin and 5-fluorouracil EORTC el Tratamiento de EORTC phase II study of CisGem combined with or without panitumumab Closed to Gastrointestinal Tumores Digestivos, Gastrointestinal EORTC Gastrointestinal 40101 POWER 1607 with pembrolizumab in patients with Recruiting for patients with nonresectable, Patient Entry Tract Cancer Arbeitsgemeinschaft Tract Cancer Tract Cancer Group advanced or metastatic biliary tract advanced or metastatic esophageal Group Internistische Onkologie, Group cancer squamous cell cancer (ESCC) Arbeitsgemeinschaft Medikamentöse Adjuvant immunotherapy in patients Tumortherapie with resected gastric cancer following EORTC preoperative chemotherapy with high Gastrointestinal EORTC Gastrointestinal 1707 VESTIGE Recruiting risk for recurrence (N+ and/or R1): an Tract Cancer Tract Cancer Group open label randomized controlled Group EORTC phase-2-study (VESTIGE) Screening Platform of the EORTC for Closed to Gastrointestinal EORTC Gastrointestinal 40CRC SPECTAcolor Clinical Trials in Advanced Colorectal Patient Entry Tract Cancer Tract Cancer Group Phase II trial in inoperable cancer “SPECTAcolor” œsophageal cancer evaluating EORTC Group EORTC Gastrointestinal the feasibility of the combination Closed to Gastrointestinal 1714 CRUCIAL Tract Cancer Group,EORTC of definitive chemoradiation with Patient Entry Tract Cancer Radiation Oncology Group the immune checkpoint blockers Group Nivolumab +/- Ipilimumab (CRUCIAL) A prospective randomised phase UNICANCER,EORTC III study of androgen deprivation EORTC Gastrointestinal Genito-Urinary Cancers Trial of preoperative therapy for therapy (+/- docetaxel) with or without EORTC Genito- Tract Cancer Group,EORTC Closed to Group,EORTC Radiation gastric and esophagogastric junction 1201 PEACE-1 local radiotherapy with or without Urinary EORTC Radiation Oncology Patient Entry Oncology Group,Groupe adenocarcinoma. A randomized abiraterone acetate and prednisone Cancers Group Gastrointestinal Group,Australasian d'Etude des Tumeurs Uro- 22114 TOP GEAR phase II/III trial of preoperative Recruiting in patient with metastatic hormone- Tract Cancer Gastro-Intestinal Trials Genitales chemoradiotherapy versus naïve prostate cancer. Group Group,Trans-Tasman preoperative chemotherapy for Radiation Oncology Group resectable gastric cancer. EORTC Genito-Urinary Inc Cancers Group,Groupe d'Etude des Tumeurs EORTC Gastrointestinal A Randomized multicenter phase Uro-Genitales,Cancer Tract Cancer Group,EORTC III trial comparing enzalutamide Trials Ireland / Radiation Oncology vs. a combination of Ra223 and EORTC Genito- ICORG,Canadian Urologic Group,Federation 1333 PEACE III enzalutamide in asymptomatic Recruiting Urinary Preoperative chemoradiotherapy Oncology Group,Grupo EORTC Francophone or mildly symptomatic castration Cancers Group and postoperative chemotherapy Latino Americano de LT-FU Gastrointestinal de Cancerologie resistant prostate cancer patients 40054 PETACC-6 with capecitabine and oxaplatin Investigações Clínicas em ongoing Tract Cancer Digestive,Australasian metastatic to bone. vs.capecitabine alone in locally Oncologia / Latin American Group Gastro-Intestinal Trials advanced rectal cancer (PETACC-6). Cooperative Oncology Group,Arbeitsgemeinschaft Group Internistische Onkologie,Belgian Group of A Randomized phase III trial UNICANCER,EORTC Digestive Oncology comparing conventional-dose Genito-Urinary Cancers A phase II-R and a phase III trial chemotherapy using paclitaxel, Group30,Cancer ifosfamide, and cisplatin (TIP) with Trials Ireland / evaluating both *Erlotinib (PH II-R) and EORTC Gastrointestinal EORTC Genito- high dose chemotherapy using ICORG,Alliance,Institute of chemoradiation (PH III) as adjuvant EORTC Tract Cancer 1407 TIGER Recruiting Urinary treatment for patients with resected Closed to Gastrointestinal Group40,EORTC mobilizing paclitaxel plus ifosfamide Cancer Research - Clinical 40084 Cancers Group head of pancreas adenocarcinoma Patient Entry Tract Cancer Radiation Oncology followed by High-dose carboplatin Trials & Statistics Unit,The *(PH II-R Erlotinib randomization Group Group22,Radiation and etoposide (TI-CE) as first salvage Australian and New completed, arm 2 closed to accrual Therapy Oncology Group treatment in relapsed or refractory Zealand Urogenital and effective 04/02/14) germ cell tumors Prostate Primary Secondary Primary Secondary Number Alias Title Status Group Groups Number Alias Title Status Group Groups Phase IIIb randomized trial comparing " Phase III trial of risk-stratified, reduced irradiation plus long term adjuvant EORTC Head androgen deprivation with GnRH intensity adjuvant treatment in Regulatory in EORTC Head and Neck EORTC Genito- EORTC Genito-Urinary 1701 PATHOS and Neck antagonist versus GnRH agonist plus patients undergoing transoral surgery Process Cancer Group 1414 Pegasus Recruiting Urinary Cancers Group,EORTC Cancer Group flare protection in patients with very for Human papillomavirus (HPV)- Cancers Group Radiation Oncology Group high risk localized or locally advanced positive oropharyngeal cancer" prostate cancer. A joint study of the A randomised phase II study to EORTC ROG and GUCG evaluate the efficacy and safety of UNICANCER,EORTC Chemotherapy (CT) vs androgen EORTC Head Head and Neck Cancer A phase 2 Randomized Open-Label 1206 deprivation therapy (ADT) in patients Recruiting and Neck Group,Réseau d’Expertise Study of Oral ODM-201 vs. androgen EORTC Genito- EORTC Genito-Urinary with recurrent and/or metastatic, Cancer Group Français sur les Cancers 1532 ODM-201 deprivation therapy (ADT) with LHRH Recruiting Urinary Cancers Group androgen receptor (AR) expressing, ORL Rares agonists or antagonist in Men with Cancers Group salivary gland cancer (SGCs) Hormone Naive Prostate Cancer EORTC Head and Neck Cancer Group,EORTC EORTC Genito-Urinary Randomised phase 3 trial of Radiation Oncology Cancers Group,Cancer Enzalutamide in Androgen EORTC Genito- Phase III study assessing the “best Group,Schweizerisches Closed to Trials Ireland / ICORG,The 1545 EnzaRAD Deprivation therapy with radiation Urinary of” radiotherapy compared to the Arbeitsgemeinschaft Klin. Patient Entry Australian and New therapy for high risk, clinically Cancers Group “best of” surgery (trans-oral surgery EORTC Head Krebsforschung,Groupe Zealand Urogenital and localised, prostate cancer. 1420 Best Of (TOS)) in patients with T1-T2, N0- Recruiting and Neck d'Oncologie et Prostate N1 oropharyngeal, supraglottic Cancer Group Radiotherapie Tete et carcinoma and with T1, N0 Cou,National Cancer EORTC Genito-Urinary hypopharyngeal carcinoma Research Institute - Randomized Phase III trial comparing Cancers Group,National Head & Neck Cancer immediate versus deferred EORTC Genito- LT-FU Cancer Research Grp,Interdisziplinäre AG 30073 SURTIME nephrectomy in patients with Urinary ongoing Institute - Renal Cancer Kopf-Hals-Tumoren synchronous metastatic renal cell Cancers Group Group,Canadian Urologic carcinoma. A pilot study of personalized Oncology Group UNICANCER,EORTC biomarker-based treatment strategy EORTC Head Head and Neck Cancer or immunotherapy in patients with A Randomised Phase II Study of 1559 UPSTREAM Recruiting and Neck Group24,National Cancer Scottish Gynaecological recurrent/metastatic squamous Nintedanib (BIBF 1120) compared EORTC Cancer Group Research Institute - Head & Closed to Cancer Trials Group,EORTC cell carcinoma of the head and neck 1212 NiCCC to Chemotherapy in Patients with Gynecological Neck Cancer Grp Patient Entry Gynecological Cancer (UPSTREAM) Recurrent Clear Cell Carcinoma of the Cancer Group Group Ovary or Endometrium (NiCCC) Late Toxicity and Long-term Quality EORTC Head EORTC Head and Neck 1629 of Life in Head and Neck Cancer Recruiting and Neck Cancer Group,EORTC A phase II study of the anti-PD-L1 Survivors Cancer Group Quality of Life Group antibody atezolizumab, bevacizumab and acetylsalicylic acid to investigate EORTC Closed to EORTC Gynecological 1508 safety and efficacy of this combination Gynecological Patient Entry Cancer Group in recurrent platinum-resistant Cancer Group Randomized Phase II study of ovarian, fallopian tube or primary Cisplatin plus Radiotherapy versus peritoneal adenocarcinoma Durvalumab plus Radiotherapy followed by Adjuvant Durvalumab EORTC Head EORTC Head and Neck 1740 LA-OSCC versus Durvalumab plus Radiotherapy Recruiting and Neck Cancer Group,Canadian Phase IB-II, open label, multicentre followed by Adjuvant Tremelimumab Cancer Group Cancer Trials Group feasibility study of Pazopanib in EORTC and Durvalumab in Intermediate Risk combination with Paclitaxel and Closed to EORTC Gynecological 55092 Gynecological HPV-Positive Locoregionally Advanced Carboplatin in patients with platinum- Patient Entry Cancer Group Cancer Group Oropharyngeal Squamous Cell Cancer refractory/resistant ovarian, fallopian (LA-OSCC) tube or peritoneal carcinoma. A randomized phase III multicenter Randomized phase III study of trial of neoadjuvant docetaxel neoadjuvant chemotherapy followed (Taxotere) EORTC Head by surgery vs. EORTC plus cisplatin plus 5-fluorouracil LT-FU EORTC Head and Neck Closed to EORTC Gynecological 24971 and Neck 55994 concomitant radiotherapy and Gynecological versus neoadjuvant cisplatin plus ongoing Cancer Group Patient Entry Cancer Group Cancer Group chemotherapy in Cancer Group 5-fluorouracil in patients with locally FIGO Ib2, IIa > 4 cm or IIb cervical advanced inoperable squamous cell cancer. carcinoma of the head and neck Primary Secondary Primary Secondary Number Alias Title Status Group Groups Number Alias Title Status Group Groups EORTC Lung Cancer Empirical versus pre-emptive Targeted therapy with or without dose Group,EORTC Radiation (diagnostic-driven) antifungal therapy intensified radiotherapy for oligo- EORTC Lung of patients treated for haematological 1702 HALT Recruiting Oncology Group,National EORTC EORTC Leukemia progressive disease in oncogene- Cancer Group malignancies or receiving an Closed to Cancer Research Institute - 65091 Infectious Group,EORTC Infectious addicted lung tumours allogeneic stem cell transplant. A Patient Entry Lung Cancer Group Diseases Group Diseases Group therapeutic open label phase III strategy study of the EORTC Infectious Activity of Lorlatinib based on ALK resistance mutations on blood in ALK Diseases and Leukemia Groups ALKALINE EORTC Lung 1825 positive NSCLC patients previously Recruiting EORTC Lung Cancer Group trial Cancer Group 10-day decitabine versus conventional treated with 2nd generation ALK chemotherapy (“3+7”) followed by inhibitor EORTC Leukemia allografting in AML patients >= 60 EORTC Closed to Group,Gruppo Italiano 1301 AML21 years: a randomized phase III study Leukemia Phase III study comparing post- Institut Gustave Patient Entry Malattie Ematologiche of the EORTC Leukemia Group, CELG, Group operative conformal radiotherapy Roussy,EORTC Lung dell'Adulto GIMEMA and German MDS Study to no post-operative radiotherapy in Cancer Group,EORTC Closed to EORTC Lung Group 22055 LUNG-ART patients with completely resected Radiation Oncology Patient Entry Cancer Group non-small cell lung cancer and Group,Intergroupe A randomised, open-label phase mediastinal N2 involvement - LUNG- Francophone de III trial evaluating the addition of EORTC Lung Cancer ETOP5-12 Closed to EORTC Lung ART Cancérologie Thoracique 08111 denosumab to standard first-line Group,European Thoracic (SPLENDOUR) Patient Entry Cancer Group anticancer treatment in advanced Oncology Platform Very early FDG-PET-response adapted NSCLC EORTC targeted therapy for advanced 1537 COBRA Recruiting Lymphoma EORTC Lymphoma Group Hodgkin lymphoma: a single-arm Nintedanib as maintenance treatment Group of malignant pleural mesothelioma phase II study EORTC Lung 08112 NEMO (NEMO): a double-blind randomized Recruiting EORTC Lung Cancer Group Cancer Group phase II study of the EORTC Lung EORTC Lymphoma Cancer Group Group,Australasian Leukaemia and Lymphoma EORTC Lung Cancer Genetics of EGFR Mutation Study Group,NCIC Clinical Trial Closed to EORTC Lung Group,National Cancer BEACOPP (4 cycles escalated + 4 cycles EORTC 08114 GEM (GEM): a Translational Study of the LT-FU Group,Nordic Lymphoma Patient Entry Cancer Group Research Institute - Lung 20012 BEACOPP baseline) versus ABVD (8 cycles) in Lymphoma EORTC Lung group ongoing Group,Grup per l'Estudi del Cancer Group stage III & IV Hodgkin's Lymphoma Group Limfomes de Catalunya i EORTC randomized phase II study Balears,National Cancer of pleurectomy/ decortication Research Institute - EORTC Lung 1205 (P/D) preceded or followed by Recruiting EORTC Lung Cancer Group Lymphoma Group-UK Cancer Group chemotherapy in patients with early The H10 EORTC/GELA/IIL randomized stage malignant pleural mesothelioma Intergroup trial on early FDG-PET EORTC Lymphoma scan guided treatment adaptation EORTC LT-FU Group,Italian Lymphoma SPECTAlung: Screening Patients with EORTC Lung Cancer 20051 H10 versus standard combined Lymphoma Closed to EORTC Lung ongoing Foundation,Lymphoma 1335 SPECTAlung thoracic tumors for Efficient Clinical Group,EORTC Pathobiology modality treatment in patients Group Patient Entry Cancer Group Study Association Trial Access Group with supradiaphragmatic stage I/II Hodgkin's lymphoma. A randomized, phase 3 trial with anti-PD-1 monoclonal antibody EORTC Lung Cancer pembrolizumab (MK-3475) versus Closed to EORTC Lung Brentuximab vedotin associated with 1416 PEARLS Group,European Thoracic EORTC Lymphoma placebo for patients with early stage Patient Entry Cancer Group chemotherapy in untreated patients EORTC Oncology Platform Closed to Group,Italian Lymphoma NSCLC after resection and completion 20113 BREACH with stage I/II unfavourable Hodgkin's Lymphoma Patient Entry Foundation,Lymphoma of standard adjuvant therapy lymphoma. A randomized phase II Group Study Association LYSA-FIL-EORTC intergroup study A phase II study of etoposide and cis/carboplatin with or without Closed to EORTC Lung 1417 REACTION EORTC Lung Cancer Group pembrolizumab in untreated Patient Entry Cancer Group extensive small cell lung cancer Phase III study on Hodgkin's disease EORTC APPLE trial:Feasibility and activity LT-FU 20881 H7 supradiaphragmatic clinical stages I Lymphoma EORTC Lymphoma Group of AZD9291(osimertinib) treatment Closed to EORTC Lung ongoing 1613 APPLE EORTC Lung Cancer Group and II Group on Positive PLasma T790M in EGFR Patient Entry Cancer Group mutant NSCLC patients Primary Secondary Primary Secondary Number Alias Title Status Group Groups Number Alias Title Status Group Groups Combination of targeted therapy Prospective randomized controlled (Encorafenib and Binimetinib) trial of adjuvant involved field EORTC EORTC Lymphoma followed by combination of LT-FU 20884 H3-4 radiotherapy after MOPP/ABV hybrid Lymphoma Group,Pierre et Marie Curie immunoterapy (Ipilimumab and EORTC ongoing chemotherapy in advanced Hodgkin Group Group 1612 EBIN Nivolumab) vs immediate combination Recruiting Melanoma EORTC Melanoma Group disease. H34 Trial of immunotherapy in patients with Group unresectable or metastatic melanoma with BRAF V600 mutation: an EORTC phase II randomized study (EBIN) Protocol H8 for a prospective controlled trial in stage I-II Adjuvant peginterferon alpha-2b for supradiaphragmatic Hodgkin's EORTC LT-FU 2 years vs Observation in patients 20931 H8 disease. Evaluation of treatment Lymphoma EORTC Lymphoma Group EORTC EORTC Melanoma ongoing with an ulcerated primary cutaneous LT-FU efficacy and (long term) toxicity in Group 18081 Melanoma Group,NCIC Clinical Trial melanoma with T(2-4)bN0M0: a ongoing three different prognostic subgroups. Group Group randomized phase III trial of the H8 Trial EORTC Melanoma Group

Adjuvant ganglioside GM2-KLH/QS-21 A Phase III randomized study on low- Vaccination dose total body irradiation EORTC EORTC Lymphoma Post-operative adjuvant ganglioside and involved field radiotherapy in Closed to GM2-KLH/QS-21 vaccination EORTC 20971 Lymphoma Group,EORTC Radiation LT-FU patients with localized, Patient Entry 18961 treatment vs observation after Melanoma EORTC Melanoma Group Group Oncology Group ongoing stages I and II, low grade non- resection of primary cutaneous Group Hodgkin's lymphoma melanoma (AJCC stage II, T3-T4N0M0), a 2-arm multicenter randomized phase III trial Prospective controlled trial in clinical stages I-II supradiaphragmatic Cross-tumoral Phase 2 clinical trial EORTC EORTC Hodgkin'Disease. Evaluation of LT-FU exploring crizotinib (PF-02341066) 20982 H9 Lymphoma EORTC Lymphoma Group Closed to Network EORTC Network of Core treatment efficacy, (long term) toxicity ongoing 90101 CREATE in patients with advanced tumors Group Patient Entry of Core Institutions and Quality of Life in two different induced by causal alterations of ALK Institutions prognostic subgroups. and/or MET ("CREATE")

Neoadjuvant afatinib based treatment EORTC Adjuvant immunotherapy with strategies followed by surgery in EORTC Network of Core LT-FU Network anti-CTLA-4 monoclonal antibody 90111 squamous cell carcinoma of the head Institutions,EORTC Head (ipilimumab) versus placebo after EORTC ongoing of Core LT-FU and neck: an EORTC NOCI-HNCG and Neck Cancer Group 18071 complete resection of high-risk Stage Melanoma EORTC Melanoma Group Institutions ongoing window study III melanoma : A randomized, double- Group blind Phase 3 trial of the EORTC Assessment of the Quality of Life Melanoma Group. of childhood acute lymphoblastic Closed to EORTC Quality 1620 leukemia patients enrolled in EORTC Patient Entry of Life Group Children Leukemia Group trials Minitub: Prospective registry on between 1971 and 1998 Sentinel Node (SN) positive melanoma EORTC patients with minimal SN tumor Comparison of the EORTC QLU-C10D 1208 MiniTub Recruiting Melanoma EORTC Melanoma Group burden who undergo Completion with generic utility instruments and EORTC Quality Group 1622 Recruiting EORTC Quality of Life Group Lymph Node Dissections (CLND) or development of a comprehensive of Life Group Nodal Observation. manual for its use

Late Toxicity and Long-term Quality EORTC Quality Adjuvant immunotherapy with 1629 of Life in Head and Neck Cancer Recruiting of Life Group anti-PD-1 monoclonal antibody Survivors Pembrolizumab (MK-3475) versus EORTC Closed to 1325 placebo after complete resection Melanoma EORTC Melanoma Group Patient Entry Understanding long-term implications of high-risk Stage III melanoma: A Group of brain tumor treatment on HRQOL Regulatory in EORTC Quality randomized, double- blind Phase 3 1721 EORTC Brain Tumor Group and cognitive functioning: a European Process of Life Group trial of the EORTC Melanoma Group cross-sectional study Primary Secondary Primary Secondary Number Alias Title Status Group Groups Number Alias Title Status Group Groups Evaluating the use of the EORTC PRO EORTC Quality An international field study for the 1726 measures for improving inter-rater Recruiting of Life Group reliability and validity of the EORTC reliability of CTCAE ratings (CTCAE) Closed to EORTC Quality 1624 Sexual Health Questionnaire (EORTC EORTC Quality of Life Group Patient Entry of Life Group SHQ-C22) for assessing sexual health Development and evaluation of an in cancer patients e-learning programme on EORTC Closed to EORTC Quality 1727 Quality of Life measures in clinical Patient Entry of Life Group practice Improving Health-Related Quality EORTC Breast Cancer of Life in Metastatic Breast Cancer. EORTC Quality Ongoing, 1722 Recruiting Group,EORTC Quality of Taking stock of achievements and of Life Group Determination of utility weights for but not in Life Group the QLU-C10D in five countries inside recruitment EORTC Quality delivering better measurement 1747 EORTC Quality of Life Group and outside Europe and analysis of as this is of Life Group their variability across populations N/A for this EORTC Breast Cancer project Group,EORTC Genito- Urinary Cancers Incorporating the patient voice in Group,EORTC sarcoma research: How can we assess EORTC Quality EORTC Soft Tissue and Phase 1-3 development of an EORTC 1749 Recruiting EORTC Quality Gynecological Cancer quality of life in this heterogeneous of Life Group Bone Sarcoma Group 1748 module assessing fertility issues and Recruiting of Life Group Group,EORTC Lymphoma group of patients? patient care needs Group,EORTC Quality Development of an EORTC module for Regulatory in EORTC Quality of Life Group,European 1837 EORTC Quality of Life Group renal cancer patients: phase I-III Process of Life Group Society for Gynecological Oncology Cutaneous T-cell and B-cell EORTC Quality 1840 Recruiting lymphomas of Life Group EORTC Brain Tumor Revision of the EORTC QLQ-BN20 brain EORTC Quality 1751 Recruiting Group,EORTC Quality of Adaption of the EORTC QLQ-Breast Regulatory in EORTC Quality EORTC Breast Cancer tumor module of Life Group 1841 Life Group Cancer Module for male BC Phase I Process of Life Group Group

Follow-up in Gynecological Cancer EORTC Gynecological EORTC Quality An International Field Study to test the 1514 Survivors: An EORTC QLG-GCG Recruiting Cancer Group,EORTC of Life Group Reliability and Validity of the EORTC Survivorship Study Quality of Life Group Anal Cancer Module (the EORTC QLQ- EORTC Quality Recruiting ANL27) and the EORTC QLQ-C30 for of Life Group Confirming content validity of the Closed to EORTC Quality 1518 EORTC Quality of Life Group assessing Health Related Quality of EORTC QLQ-C30 Patient Entry of Life Group Life in patients with Anal Cancer Development of an EORTC questionnaire for individuals at risk Closed to EORTC Quality 1522 EORTC Quality of Life Group for a Hereditary Cancer Predisposition Patient Entry of Life Group Phase 2 and 3 development of an Syndrome : the EORTC QLQ-HCPSxx Adolescent and Young Adult module Closed to EORTC Quality for 14-39 year olds & Validation of the Patient Entry of Life Group Adapt the existing EORTC QLQ- EORTC QLQ-C30 with 12-17 year olds GINET21 Module to develop a specific Closed to EORTC Quality 1523 EORTC Quality of Life Group with cancer module for use in patients with Patient Entry of Life Group Pancreatic Neuroendocrine Tumour. An international Phase 4 field study to EORTC Breast Cancer Follow-up in Early and Locally analyse the psychometric properties EORTC Quality Group,EORTC Quality EORTC Quality 1617 Advanced Breast Cancer Patients: An Recruiting of the updated module on assessing Recruiting of Life Group of Life Group,EORTC of Life Group EORTC QLG-BCG- ROG Protocol quality of life of patients with breast Radiation Oncology Group cancer EORTC Leukemia A Survivorship Project to understAnd Group,EORTC Quality of and to impRove long-Term outcomes EORTC Quality An international field study for the 1621 Recruiting Life Group,Gruppo Italiano for Acute myeloid leukemia patients of Life Group reliability and validity of the EORTC Malattie Ematologiche (SPARTA): The SPARTA Platform cancer cachexia module (the EORTC Closed to EORTC Quality dell'Adulto QLQ-CAX24) and the EORTC QLQ-C30 Patient Entry of Life Group Comparative evaluation of the for assessing quality of life in cancer EORTC Quality 1623 computer-adaptive EORTC quality of Recruiting EORTC Quality of Life Group patients with cachexia of Life Group life measures Primary Secondary Primary Secondary Number Alias Title Status Group Groups Number Alias Title Status Group Groups

An international field study for the A blind randomized multicenter study EORTC Head and Neck reliability and validity of the Phase of accelerated fractionated chemo- Cancer Group,EORTC IV EORTC Quality of Life modules for radiotherapy with or without the EORTC Radiation Oncology patients with Hodgkin’s Lymphoma hypoxic radiosensitizer nimorazole LT-FU Radiation 1219 Group,Trans-Tasman (EORTC QLQ-HL27), high-grade non- EORTC Quality (Nimoral), using a 15 gene signature ongoing Oncology Recruiting Radiation Oncology Group Hodgkin’s Lymphoma (EORTC QLQ- of Life Group for hypoxia in the treatment of Group Inc,Danish Head & Neck NHL-HG29), low-grade non-Hodgkin’s squamous cell carcinoma of the head Cancer Group Lymphoma (EORTC QLQ-NHL-LG20), and neck and Chronic Lymphocytic Leukaemia (EORTC QLQ-CLL17). Stereotactic body radiotherapy in EORTC addition to standard of care treatment Regulatory in Radiation EORTC Radiation Oncology Development of an EORTC QOL 1945 OligoRARE in patients with oligometastatic rare EORTC Quality Process Oncology Group Communication-specific module - Recruiting cancers (OligoRARE): a randomized, of Life Group Group Phases 4 phase 3, open-label trial.

Development of a questionnaire to EORTC Brain Tumor measure instrumental activities of Group,EORTC Radiation Primary chemotherapy with daily living (I-ADL) in patients with EORTC Quality EORTC Oncology Group,NCIC Recruiting temozolomide vs.radiotherapy in primary brain tumors and brain of Life Group LT-FU Radiation Clinical Trial Group,Trans- 22033 patients with low grade gliomas after metastases: Phase IV international ongoing Oncology Tasman Radiation stratification for genetic 1p loss : a field testing Group Oncology Group phase III study Inc,University College of An international field study for the London reliability and validity of the EORTC EORTC Quality Recruiting PATSAT-C33 core questionnaire and of Life Group Adjuvant postoperative high-dose EORTC EORTC Brain Tumor the EORTC OUTPATSAT7 Module radiotherapy for atypical and LT-FU Radiation 22042 Group,EORTC Radiation malignant meningioma : a Phase II and ongoing Oncology Oncology Group observation study Group Development of a QLG procedure Closed to EORTC Quality for rapid creation of symptom based Patient Entry of Life Group questionnaires EORTC Breast Cancer Group,EORTC Radiation Oncology Group,Breast Phase II and III development of an A randomized phase III study of EORTC Closed to EORTC Quality International EORTC QOL cancer survivorship radiation doses and fractionation Closed to Radiation Patient Entry of Life Group 22085 DCIS Group,Trans-Tasman questionnaire schedules for ductal carcinoma in situ Patient Entry Oncology Radiation Oncology (DCIS) of the breast. Group Group Inc,Borstkanker An international phase IV field study Onderzoeksgroup EORTC Quality for the reliability and validity of the Recruiting Nederland of Life Group EORTC Thyroid Cancer Module THY34 LungTech Stereotactic Body EORTC Radiotherapy (SBRT) of inoperable EORTC Lung Cancer Development and validation of the Closed to Radiation Closed to EORTC Quality 22113 LUNGTECH centrally located NSCLC: A phase II Group,EORTC Radiation EORTC computerized adaptive testing Patient Entry Oncology Patient Entry of Life Group study in preparation for a randomized Oncology Group (CAT) instrument - Project Extension Group phase III trial Development of thresholds for the EORTC QLQ-C30 and the EORTC CAT Phase III randomized trial Closed to EORTC Quality measures to enable their use for investigating the role of internal Patient Entry of Life Group symptom screening in daily clinical mammary and medial supraclavicular (IM-MS) lymph node practice EORTC chain irradiation in stage I-III breast EORTC Breast Cancer LT-FU Radiation 22922 cancer Group,EORTC Radiation Investigating and improving the ongoing Oncology (Joint study of the EORTC Oncology Group German response scales of the EORTC Group core questionnaire for assessing Closed to EORTC Quality Radiotherapy Cooperative Group and the quality of life in cancer patients Patient Entry of Life Group the EORTC Breast Cancer Cooperative (EORTC QLQ-C30) – a three-step Group approach EORTC 22922/10925) Primary Secondary Primary Secondary Number Alias Title Status Group Groups Number Alias Title Status Group Groups

Three Dimensional Conformal A phase II multicenter study Radiotherapy / Intensity Modulated comparing the efficacy of the oral Radiotherapy alone vs angiogenesis inhibitor nintedanib with EORTC Three Dimensional Conformal the intravenous cytotoxic compound EORTC Soft LT-FU Radiation EORTC Radiation Oncology 22991 Radiotherapy / Intensity Modulated ifosfamide for treatment of patients Closed to Tissue and EORTC Soft Tissue and ongoing Oncology Group 1506 ANITA Radiotherapy plus adjuvant hormonal with advanced metastatic soft tissue Patient Entry Bone Sarcoma Bone Sarcoma Group Group therapy in localized T1b-c, T2a, N0, sarcoma after failure of systemic Group M0 prostatic carcinoma. A Phase III non-oxazaphosporine-based first line Randomized Study. chemotherapy for inoperable disease "ANITA"

Phase II trial of cabazitaxel in EORTC Soft metastatic or inoperable locally Closed to Tissue and EORTC Soft Tissue and 1202 Reduced dose-density of denosumab EORTC Soft advanced dedifferentiated Patient Entry Bone Sarcoma Bone Sarcoma Group for maintenance therapy of Closed to Tissue and EORTC Soft Tissue and liposarcoma. Group 1762 REDUCE unresectable giant cell tumor of bone: Patient Entry Bone Sarcoma Bone Sarcoma Group a multicenter phase II study "REDUCE" Group Phase II study of cabozantinib in patients with metastatic EORTC Soft gastrointestinal stromal tumor (GIST) Closed to Tissue and EORTC Soft Tissue and A randomized phase III study 1317 CaboGist EORTC Soft who progressed during neoadjuvant, Patient Entry Bone Sarcoma Bone Sarcoma Group of neoadjuvant chemotherapy Tissue and EORTC Soft Tissue and adjuvant or palliative therapy with Group 1809 STRASS 2 followed by surgery versus surgery Recruiting Bone Sarcoma Bone Sarcoma Group imatinib and sunitinib alone for patients with High Risk Group RetroPeritoneal Sarcoma (STRASS 2) A randomised phase II trial of EORTC Soft Tissue imatinib alternating with regorafenib Phase III randomised, intergroup, EORTC Soft Tissue EORTC Soft and Bone Sarcoma compared to imatinib alone for the international trial assessing the and Bone Sarcoma Closed to Tissue and Group,Scandinavian 1321 ALT-GIST first line treatment of advanced clinical activity of STI-571 at two dose EORTC Soft Group,Scandinavian Patient Entry Bone Sarcoma Sarcoma gastrointestinal stromal tumour levels in patients with unresectable or LT-FU Tissue and Sarcoma Group Group,Australasian Gastro- 62005 (GIST). metastatic gastrointestinal stromal ongoing Bone Sarcoma Group,Australasian Intestinal Trials Group (CTC 0122/AGITG AG1013GST) tumours (GIST) expressing the KIT Group Gastro-Intestinal Trials receptor Group,Italian Sarcoma tyrosine kinase (CD117) Group EORTC Soft Tissue and Bone Sarcoma EORTC Soft Tissue Intermediate and high risk Group,Schweizerisches and Bone Sarcoma localized,completely resected, Arbeitsgemeinschaft Klin. EORTC Soft Group,Australasian International Randomised Controlled EORTC Soft gastrointestinal stromal tumors (GIST) Krebsforschung,Societe LT-FU Tissue and Gastro-Intestinal Trials Trial for the Treatment of Newly Closed to Tissue and 62024 expressing KIT receptor : a controlled 1402 EE2012 Francaise Cancer ongoing Bone Sarcoma Group,Italian Sarcoma Diagnosed Ewing’s Sarcoma Family of Patient Entry Bone Sarcoma randomized trial on adjuvant Imatinib et Leucemie des Group Group,French Sarcoma Tumours – Euro Ewing 2012 Group mesylate (Glivec) versus no further Enfants,Grupo Espanol Group,Grupo Espanol de therapy after complete surgery. de Investigacion en Investigacion en sarcomas sarcomas,University of Birmingham A phase III randomized study of EORTC Soft preoperative radiotherapy plus EORTC Radiation Oncology Closed to Tissue and EORTC Soft Tissue 62092 STRASS surgery versus surgery alone for Group,EORTC Soft Tissue Patient Entry Bone Sarcoma and Bone Sarcoma patients with Retroperitoneal and Bone Sarcoma Group Group Group,Scandinavian sarcomas (RPS) - STRASS Sarcoma Group,Italian International Randomised Controlled EORTC Soft Sarcoma A randomized double-blind EORTC Gynecological Trial of Chemotherapy for the Tissue and Group,Gesellschaft fuer 1403 rEECur Recruiting phase II study evaluating the role Cancer Group,EORTC Soft treatment of recurrent and primary Bone Sarcoma Paediatrische Onko. & of maintenance therapy with EORTC Soft Tissue and Bone Sarcoma refractory Ewing sarcoma Group Haemato. - Germany,Grupo cabozantinib in High Grade Uterine Tissue and Group,National Cancer 62113 Recruiting Espanol de Investigacion Sarcoma (HGUtS) after stabilization or Bone Sarcoma Research Institute - Gyneco en sarcomas,University response to doxorubicin +/- ifosfamide Group Cancer Group,National of Birmingham,Swiss following surgery or in metastatic first Cancer Research Institute - Paediatric Oncology Group line treatment Sarcoma Group Primary Secondary Number Alias Title Status Group Groups European European Society for EORTC-ESTRO Radiotherapy Society for 1811 E²-RADIatE Recruiting Radiotherapy and Infrastructure for Europe Radiotherapy Oncology and Oncology

Phase II open-label study with the anti-PD-L1 Atezolizumab monoclonal antibody in combination with MOTRICOLOR 1604 Bevacizumab in patients with Recruiting Vall D'Hebron Vall D'Hebron 3 advanced chemotherapy resistant colorectal cancer and MSI-like molecular signature

IMI-2- Translational Imaging Methods in Drug Research 1656 Ongoing Imaging Group TRISTAN Safety Assessment project

Central Review and correlation of PET Research 2039 scans and lymph node histology in In review Imaging Group project CTCL

The European Journal of Cancer is the official journal of the EORTC International Association under Belgian Law. Av. E. Mounier, 83/11 1200 Brussels www.eortc.org @EORTC